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1. INTRODUCTION 
In neuroscience experimentation, neurotoxins were generally considered as exogenous 
substances, administered in order to lesion a particular neural phenotype (i.e., dopaminergic 
nerves) or subset of neurons with common features (i.e., those with kainate receptors). This 
narrow definition may have been valid when selective neurotoxins were first discovered 
approximately 50 years ago, but the concept of a neurotoxin is much more global today.1  
Evolution of the science of neurotoxins has broadened the term to cover endogenous 
substances and metabolites, capable of initiating apoptotic, necrotic events leading to neuronal 
cell death. There are many pathways capable of provoking neuronal cell injury by disrupting 
normal cellular processes leading abnormal neural function that can impact neuronal interactions 
and incite events encompassed in psychiatric and substance use disorders.  
Nosology of CNS disorders now considers the putative role of environmental factors and 
interplay with genes. Accordingly, in this context, the terms "neurotoxins and neurotoxicity" are 
more global and now encompass a broad spectrum of indigenous neuronal actions - all part of the 
evolution of this area of neuroscience. Substances that damage astrocytes - satellite supportive 
cells for neurons - also produce secondary neurotoxicity.  
Loss of satellite cells leads to loss of neuronal cells. Therefore, astrocytic cytotoxins are 
deservedly included in the term 'neurotoxin'. 
Another consideration that somewhat clouds the definition of a neurotoxin is the 
observed programmed cell death that occurs during neuronal ontogeny. If a substance is released 
by one nerve to promote apoptosis in extraneous neuronal progenitor cells, the outcome is 
"normalcy". One can only wonder if it is proper to regard the chemical which signals another 
nerve to die, to produce normalcy, as a neurotoxin.  
A final consideration is the fact that a small number of repeated treatments with specific 
substances can produce long-term alterations in behavior, so that exaggerated behavioral effects 
are produced when the challenge substance is administered again, even a year or more after the 
initial short-term series of treatment. In this scenario there were seemingly no changes in 
morphology, changes in histochemical markers and numbers of receptors, nor neurotransmitter 
content or amounts of neurotransmitter released on stimulation. 
Specifically, a short course of treatment with an exquisitely low dose of the DA D2 
agonist quinpirole produced life-long enhancement of D2 agonist-mediated behaviors with no 
apparent change in any biochemical, histochemical or morphological index (Kostrzewa, 1995; 
Kostrzewa et al., 2003; 2004). This would be encompassed in the term 'neurotoxicity', because 
there is a change from normalcy.  
Neurotoxicity occurs when the exposure to natural or artificial toxic substances, which 
are called neurotoxins, alters the normal activity of the nervous system in such a way as to cause 
damage to nervous tissue. This can eventually disrupt or even kill neurons, key cells that transmit 
and process signals in the brain and other parts of the nervous system.2  
Neurotoxicity can result from exposure to substances used in chemotherapy, radiation 
treatment, drug therapies, certain drug abuse, and organ transplants, as well as exposure to heavy 
metals, certain foods and food additives, pesticides, industrial and/or cleaning solvents, 
cosmetics, and some naturally occurring substances.  
Symptoms may appear immediately after exposure or be delayed. They may include limb 
weakness or numbness, loss of memory, vision, and/or intellect, uncontrollable obsessive and/or 
compulsive behaviors, delusions, headache, cognitive and behavioral problems and sexual 
dysfunction. Individuals with certain disorders may be especially vulnerable to neurotoxins.3 
The name implies the role of a neurotoxin, although the term neurotoxic may be used 
more loosely to describe states that are known to cause physical brain damage but where no 
obvious neurotoxin has been identified. 
The term neurotoxic is used to describe a substance, condition or state that damages the 
nervous system and/or brain, usually by killing neurons. The term is generally used to describe a 
condition or substance that has been shown to result in observable physical damage.  
The presence of neurocognitive deficits alone are not usually considered sufficient 
evidence of neurotoxicity, as many substances exist which may impair neurocognitive 
performance without resulting in the death of neurons. This may be due to the direct action of the 
substance, with the impairment and neurocognitive deficits being temporary, and resolving when 
the substance is metabolised from the body.4 
In some cases the level or exposure-time may be critical, with some substances only 
becoming neurotoxic in certain doses or time periods. Some of the most common naturally 
occurring brain toxins that lead to neurotoxicity as a result of excessive dosage are Beta amyloid 
(Aβ), Glutamate and Oxygen radicals.5  
When present in high concentrations they can lead to neurotoxicity and death (apoptosis). 
Some of the symptoms that result from cell death include loss of motor control, cognitive 
deterioration and autonomic nervous system dysfunction. Additionally, neurotoxicity has been 
found to be a major cause of neurodegenerative diseases such as Alzheimer's disease (AD). 
Oxygen radicals 
The formation of oxygen radicals in the brain is achieved through the nitric oxide 
synthase (NOS) pathway. This reaction occurs as a response to an increase in the Ca2+ 
concentration inside a brain cell. This interaction between the Ca2+ and NOS results in the 
formation of the cofactor tetrahydrobiopterin (BH4), which then moves from the plasma 
membrane into the cytoplasm. As a final step, NOS is dephosphorylated yielding nitric oxide 
(NO), which accumulates in the brain, increasing its oxidative stress.6  
There are several ROS including: superoxide, hydrogen peroxide and hydroxyl, all of 
which lead to neurotoxicity. Naturally, the body utilizes a defensive mechanism to diminish the 
fatal effects of the reactive species by employing certain enzymes to break down the ROS into 
small, benign molecules of simple oxygen and water.7  
However, this breakdown of the ROS is not completely efficient; some reactive residues 
are left in the brain to accumulate, contributing to neurotoxicity and cell death. The brain is more 
vulnerable to oxidative stress, in comparison to other organs, due to its low oxidative capacity.  
Because neurons are characterized as postmitotic cells, meaning that they live with 
accumulated damage over the years, accumulation of ROS is fatal. Thus, increased levels of 
ROS age neurons, which leads to accelerated neurodegenerative processes and ultimately the 
advancement of AD.8 
 
 
 
How Antioxidants Work 
As cells function normally in the body, they produce damaged molecules called free 
radicals, which are highly unstable and steal components from other cellular molecules, such as 
fat, protein, or DNA, thereby spreading the damage. This process, called peroxidation, continues 
in a chain reaction, and entire cells soon become damaged and die. Peroxidation is important 
because it helps the body to destroy cells that have outlived their usefulness and kills germs and 
parasites. However, peroxidation, when left unchecked, also destroys or damages healthy cells. 
Antioxidants help prevent widespread cellular destruction by donating components to 
stabilize free radicals. More important, antioxidants return to the surface of the cell to stabilize, 
rather than damage, other cellular components. 
When there are no enough antioxidants to hold peroxidation in check, free radicals begin 
damaging healthy cells, which can lead to problems. For example, free radical damage to 
immune cells can lead to an increased risk of infections. 
Flavonoids are low molecular weight bioactive poly phenols9 which play a vital role in 
photo synthesizing cells. The original "flavonoid" research apparently began in 1936, when 
Hungarian scientist Albert Szent-Gyorgi was uncovering a synergy between pure vitamin C and 
as yet un  identified co-factors from the peels of lemons, which he first called "citrin," and later, 
"vitamin P".10 
Flavonoids have been reported to exert wide range of biological activities. These include, 
anti-inflammatory, antibacterial, antiviral, anti-allergic,10 cytotoxic anti-tumour treatment, 
neurodegenerative diseases and vasodilator action.11 In addition flavonoids are known to inhibit 
lipid-peroxidation, platelet aggregation, capillary permeability and fragility, cyclo-oxygenase 
and lipoxygenase enzyme activities.  
They exert these effects as antioxidants, free radical scavengers, cheaters of divalent 
cation.12 These are also reported to inhibit variety of enzymes like hydrolases, hyalouronidase, 
alkaline phosphatise, aryl sulphates, cAMP phosphodiesterase, lipase, α-glucosidase and 
kinase.13 
 
Diosmin is a naturally occurring flavonoid glycoside, it is a member of the citrus 
flavonoid family and is a modified form of hesperidin.14 It is a semisynthetic drug that is used as 
an oral phlebotropic drug in the treatment of venous disease, i.e., chronic venous insufficiency 
and haemorrhoidal disease. Diosmin prolong the vasoconstrictor effect of nor epinephrine on the 
vein wall, increased the venous tone, and therefore reduces venous capacitance, distensibility, 
and stasis.14 Diosmin has been found to be effective in mitigating hyperglycaemia in diabetic 
rats.15  
Its anti-inflammatory and anti-apoptotic activity has been demonstrated in neuronal cells. 
Until now, however, clinical studies of the effects of Diosmin have been in conclusive. 
Furthermore, only a limited number of articles have been published and few articles are available 
on the use of diosmin. Based on the previous studies I like to carry out the evaluation of 
neuroprotective activity of Diosmin on Wistar rats. 
A) ARSENIC INDUCED NEUROTOXICITY 
The word arsenic is derived from the Persian zarnikh. As was used in traditional Chinese and 
Indian medicine and as a cosmetic product in eye shadow in the Roman era. Arsenic is used in 
folk medicine and in pesticides in many countries and also in modern western medicine for the 
treatment of leukemia. In traditional Chinese medicine, preparations can be obtained in the form 
of coated or uncoated pills, powder or syrups.16 
Arsenic is used in folk medicine and in pesticides in many countries and also in modern 
western medicine for the treatment of leukemia.17,18 In traditional Chinese medicine, preparations 
can be obtained in the form of coated or uncoated pills, powder or syrups. Different studies have 
shown that the majority of traditional Chinese medicines, such as Chinese herbal balls, show 
high doses of As varying between 0.1 and 36.6 mg per tablet, causing patients to get intoxicated 
by the high As dose, and Indian ayurvedic herbal medicine products are also known to cause 
lead, mercury and As intoxication.19-22  
Nowadays, the therapeutic use of As is making a comeback in modern medicine. Arsenic 
trioxide (ATO), for instance, is used to treat patients with relapsed acute promyelocytic leukemia 
(APL).23-26 But ATO is also known for its less favorable side, as in causing temporary cardiac 
and neurotoxic side effects in APL patients.18  
Arsenic was one of the primary ingredients in pesticides before synthetic organic 
pesticides were available; its long-term application in agricultural pesticides has resulted in high 
levels of arsenic in the body of workers, who are exposed by inhalation during the spraying. 
Arsenic-containing rodent pesticides used for pest and insect control were banned due to human 
health concerns in production, use, and accidental poisoning and possible abuse in intentional 
poisoning. Various case reports and studies have revealed that exposure to As has resulted in 
various forms of cancer and peripheral neuropathy.17,27, 28  
Acute and chronic exposure to arsenic 
Acute: 
 A single exposure, to a high dose may lead to severe reactions such as diarrhea, 
vomiting, pain, dehydration and weakness. Nowadays, acute intoxication rarely occurs in 
western European countries; if it occurs, it is usually the result of intentional (suicide or 
homicide) or accidental poisoning. Occupational exposure to As is rare and usually occurs in the 
form of arsine gas, which causes symptoms different to those caused by As ingestion.29 
Exposure often occurs when arsine gas escapes during transport or when it is generated 
while arsenic-containing ores or metals are treated with acid.30,31 Acute oral exposure to As is 
associated with gastrointestinal symptoms such as nausea, vomiting, abdominal pain and severe 
diarrhea. Cardiovascular and respiratory symptoms include hypotension, shock, pulmonary 
edema and heart failure. If survived, acute poisoning with As is also combined with neurological 
symptoms like light-headedness, weakness, delirium, encephalopathy and peripheral neuropathy, 
which have been reported.32 
Peripheral neuropathy as a result of As intoxication may be delayed several weeks after 
the initial toxic insult.33 After a few weeks the patients show signs of recovery, however, when 
tested with electrophysiological studies 6 to 8 years after exposure, the patients still showed 
reduced motor conduction velocity.33 
Chronic  
Environmental and occupational As exposure is not only caused by contaminated 
drinking water due to the leaching of natural geological resources, but may also occur from 
mining and other industrial processes.34 
Chronic ingestion of low concentration of As levels can occur through industrial 
accidents, work and environment, which eventually may cause a higher tolerance for As. An 
example of such an industrial accident can be found in the early 20th century, in reports on As 
intoxication caused by contaminated beer in Salford, UK. The patients, had a few symptoms in 
common, they all suffered from ‘peripheral neuritis’ characterized by weakness in the limbs that 
made it difficult for them to walk. 35,36 
In several cases some of the patients suffered from rashes and itching, sometimes these 
complaints were accompanied by darkening of skin texture. The presence of As in the beer was 
due to the use of contaminated glucose and inverted sugar by the brewers. Furthermore, the 
contamination of this sugar is caused by the use of very impure sulphuric acid. The source of As 
contamination was traced back to invert sugar, which was caused by the action of sulphuric acid 
on various forms of starch. The original source was the Spanish pyrites from which the sulphuric 
acid was made and often contained large percentages of As. 
Chronic As poisoning represents a global, serious health concern, if As can be found in 
high concentrated levels in the environment from natural or industrial processes. Arsenic 
contamination of groundwater has occurred in various parts of the world such as in the Americas, 
Bangladesh, India, Taiwan and many other Asian countries. In Bangladesh, a country of 125 
million, between 35-77 million people are currently exposed to As through drinking water, 
which is also the major cause of death, especially among children.37,38 
As a quick and inexpensive solution for the lack of sufficient and clean drinking water, 
UNICEF and the World Bank advocated to tap into deeper groundwater. Millions of wells were 
constructed; infant mortality and gastrointestinal illness were reduced by half. However, later 
studies revealed that over 40% of these wells are contaminated with arsenic. As a result, due to 
the daily exposure to As in their drinking water, the population in south east Asia has to endure 
various ailments caused by As.  
Chronic symptoms of As exposure are pigmentation changes, gastrointestinal symptoms, 
anemia, liver disease, a metallic taste and Mees’ lines on the nails,39 blackfoot disease and 
diabetes mellitus.40 Apart from pigmentation changes, arsenic-induced skin pathology caused by 
chronic intoxication also causes hyperkeratosis, Bowen’s disease, squamous cell carcinoma and 
basal cell carcinomas.41,42  
Hafemann et al. (2005) have shown an association between arsenic exposure and 
peripheral neuropathy in the Bangladesh population that has been chronically exposed to arsenic 
in drinking water. They showed that increased As exposure, as measured by both cumulative and 
urinary measures, was associated with evidence of sub-clinical sensory neuropathy. The 
correlation between As exposure and neuropathy was shown with the increased vibrotactile 
threshold, a sign of subclinical sensory neuropathy and sub-clinical loss of vibratory sensation in 
the lower extremities.43 
 
 
 
Kinetics of various arsenic metabolites and their molecular mechanism of toxicity 
Kinetics. 
Arsenic absorption takes place mainly in the small intestines; also a minimal absorption 
occurs from skin contact and inhalation.41,44,45 After ingestion, As is metabolized from inorganic 
to organic compounds with varying degrees of toxicity and the behavior of the different As 
species vary markedly. Arsenic speciation of inorganic and organic forms of As is often as 
important as total quantification, because of their different toxicity and mobility.46 
As speciation in biological samples is an essential tool to gain insight into its distribution 
in tissues and its specific toxicity to target organs. Arsenic metabolites exist both in organic and 
inorganic forms and both types can exist in either trivalent or pentavalent oxidation states. The 
bioavailability of inorganic As is up to 60%. Inorganic As such as arsenate (iAsV), the 
pentavalent form, and arsenite (iAsIII), the trivalent form, are the most aggressive single-
substance toxicants, specially the trivalent form. 
A redox reaction reduces the pentavalent As to its trivalent state. This reduction step from 
pentavalent to trivalent, releases a more toxic compound, which in fact results in bioactivation. 
Fig. 1: Metabolic pathways of arsenate methylation 
 Above mentioned figure explains the two possible pathways for arsenate methylation. 
The main pathway is a straightforward bioactivation (metabolic activation) of arsenate in MMA, 
DMA and the theoretical conversion into TMA (not shown).47,48,49 A possible second pathway is 
direct metabolism of iAs (A) to either MMA without further conversion to DMA or (B) increase 
in DMA levels, while the MMA levels stay intact.50 
Arsenic metabolism shows a common route of absorption, distribution and excretion both 
in humans and various animals with subtle interspecies differences. Metabolism of inorganic As 
starts with intake and absorption. Distribution of As varies per species. This is a result of various 
factors such as species, bodyweight, route of intake and duration of exposure. After its 
absorption, As can be found in different organs, especially in the liver.50,52 
Arsenic undergoes hepatic biomethylation to form monomethyl arsenic (MMA) and 
dimethyl arsenic (DMA). Detoxification starts with transformation of inorganic As to organic As 
and reduction of pentavalent arsenate to trivalent arsenite, which results in a more toxic 
component. The reduction of arsenate to arsenite is catalyzed by gluthatione (GSH) and other 
thiols, which are reducing agents.45 Arsenate at physiological pH is ionized and as such is not 
able to pass cellular membranes. Conversion to arsenite at physiological pH facilitates passage 
through the cellular membrane. 
Metabolism of As continues by using arsenite as its substrate for methylation, which is 
distributed in tissues and cytosol. However, methylation does not appear to be the primary 
detoxification pathway for arsenite. Protein binding has been suggested as the initial protective 
mechanism. Arsenite binding to protein serves as a reservoir and takes place after initial increase 
in arsenite concentration. When methylation enzymes start to become effective, the reservoir 
may slowly release small amounts of arsenite for methylation.52,53 
The methylation of arsenite is catalyzed by a specific methyltransferase using                  
S-Adenosyl methionine as a methyl donating cofactor (SAM).43,47 Addition of a methyl group to 
arsenite leads to synthesis of pentavalent monomethylarsonic (MMAV). The MMAV in turn is 
reduced to trivalent MMA (MMAIII) by GSH, the reducing agent. Another round of 
methyltransferase activity with MMAIII results in production of dimethylarsenic acid (DMA). 
However, it is not clear whether the same SAM is used for methylation of MMA and 
DMA or that two separate SAMs are being used for these two methylation steps. Theoretically, 
conversion of arsenate to DMA could be extended by one more round to achieve 
trimethylarsenic acid (TMA).52,54 A second possible conversion route to MMA and DMA was 
introduced by the in vitro studies of Buchet and Lauwerys, by adding mercuric ions; they 
prevented the formation of DMA without affecting MMA formation.50,51 
Furthermore, it was evident that the addition of cyanocobalamin or methyl- 
cyanocobalamin (vitamin B12) and coenzyme B12 in combination with SAM resulted in a 
significant increase of DMA and no additional increase in MMA level. This experiment revealed 
two different enzymatic activities involved in methytransferase to either MMA or DMA. 
The methylation process has been thought to be the detoxification mechanism for As. 
This is true when this line of reasoning is applied to parameters of acute toxicity of As species, 
such as LC50 or LD50. As a rule, the trivalent As compounds are more cytotoxic then their 
pentavalent forms. However, various studies in animals and cell cultures have shown the adverse 
effects of methylated As, such as DMAV as a tumor promoter 55,56  or direct genotoxic action of 
MMAIII and DMAIII in vitro.52 
The main excretion route of As is through the urine and bile. However, the various As 
metabolites do not excrete in the same fashion in different animals and humans. For example, 
studies in rats have shown that pentavalent metabolites such as iAsV, MMAV and DMAV are 
exclusively excreted into urine, MMAIII only into bile and iAsIII into both bile and urine.57 In 
contrast, human studies revealed the presence of MMAIII in urine.48,58 Arsenic studies carried 
out by Csanaky and Gregus in rats, mice, hamsters, rabbits and guinea pigs revealed some 
similarities. All species injected with iAsV excreted various As metabolites into urine, in 
contrast to injection with iAsIII, which showed higher excretion into bile rather than urine.57  
Mechanism 
These metabolites exert their toxicity by inactivating many enzymes, especially those 
involved in the cellular energy pathway and DNA synthesis and repair. Arsenic is substituted for 
phosphate in high-energy compounds such as ATP. Arsenic binds covalently with sulfhydryl 
groups in their reduced form. These interactions also take place with certain enzymes necessary 
for cellular metabolism.27 
Various As carcinogenesis studies have revealed that As may alter one or more DNA 
repair processes. Andrew et al. have shown that patients exposed to As have altered nucleotide 
excision repair mainly on the excision repair cross-complementing 1 (ERCC1) component.  
Arsenic exposure was associated with decreased expression of ERCC1 in isolated lymphocytes 
at the mRNA and protein levels.59 
In short, As exposure results not only in general toxicity but also in neuronal diseases and 
carcinogenesis. Tri-valent arsenic (iAsIII, MMAIII and DMAIII) compounds are thought to 
interact with thiol groups of proteins and enzymes in their reduced state. This is believed to 
inhibit the catalytic activity of enzymes.58 The common thinking is that tri-valent arsenic 
metabolites inhibit pyruvate dehydrogenase (PDH), which leads to disruption of the energy 
system of the cell,59 which in turn may release an apoptosis-inducing factor (AIF) resulting in 
cell damage and death.  
AIF is released from the mitochondrial intermembrane space from where it translocates 
to the cell nucleus.60 Apoptosis is associated with early formation of ring-like perinuclear 
condensed chromatin co-localized with AIF, DNA fragmentation and finally cell death. 
Pentavalent As (iAsV, MMAV and DMAV) is substituted for phosphorus in many biochemical 
reactions. Replacing the stable phosphorus anion in phosphate with the less stable AsV anion 
leads to rapid hydrolysis of high-energy bonds in compounds such as ATP. At the level of the 
citric acid cycle, As inhibits succinate dehydrogenase and by competing with phosphate it 
uncouples oxidative phosphorylation, thus inhibiting energy-linked reduction of NAD+, 
mitochondrial respiration, and ATP synthesis. This leads to loss of high-energy phosphate bonds 
and effectively uncouples oxidative phosphorylation.61,49 
Another approach is that trivalent As inhibits enzyme complexes by reactive oxygen 
species (ROS), indicating that ROS production by trivalent As causes pyruvate dehydrogenase 
(PDH) inactivation through oxidation.62 Inactivation through oxidation causes impaired 
gluconeogenesis and reduced oxidative phosphorylation.63 Production of ROS by As was 
determined by use of a nonfluorescent dye 5’,6’-chlomethyl-2’,7’-dichlorodihydrofluorscein 
(CM-H2DCFDA), which is a non-specific radical detector to identify the radical species.64 
 
 
Pharmacological and Toxicological Effects of Arsenic 65 
Arsenicals have varied effects on many organ systems, as summarized below.  
Cardiovascular System 
Acute and subacute doses of inorganic arsenic induce mild vasodilation. Serious 
cardiovascular effects include hypotension, congestive heart failure, and cardiac arrhythmias. 
Long-term exposure results in peripheral vascular disease, more specifically gangrene of the 
extremities, especially of the feet, often referred to as blackfoot disease. Myocardial damage and 
hypotension may become evident after more prolonged exposure to arsenic.  
Gastrointestinal Tract 
Acute or subacute exposure to arsenic can produce GI disturbances, with chronic 
exposure to arsenic, GI effects usually are not observed. Small doses of inorganic arsenicals, 
especially the trivalent compounds, cause mild splanchnic hyperemia. Normal proliferation of 
the epithelium is suppressed, which accentuates the damage. Soon the feces become bloody. 
Damage to the upper GI tract usually results in hematemesis. Stomatitis also may be evident. The 
onset of GI symptoms may be so gradual that the possibility of arsenic poisoning may be 
overlooked.  
Kidneys 
The action of arsenic on the renal capillaries, tubules, and glomeruli may cause severe 
renal damage. Initially, the glomeruli are affected, and proteinuria results. Varying degrees of 
tubular necrosis and degeneration occur later. Oliguria with proteinuria, hematuria, and casts 
frequently results from arsenic exposure.  
Skin 
Skin is a major target organ of arsenic. Diffuse or spotted hyperpigmentation over the 
trunk and extremities usually is the first effect observed with chronic arsenic ingestion. Long-
term ingestion of low doses of inorganic arsenicals causes cutaneous vasodilation and a "milk 
and roses" complexion. Eventually, skin cancer is observed.  
 
 
Blood 
Inorganic arsenicals affect the bone marrow and alter the cellular composition of the 
blood. Hematological evaluation usually reveals anemia with slight-to-moderate leukopenia; 
eosinophilia also may be present. The vascularity of the bone marrow is increased.  
Liver 
Inorganic arsenicals and a number of now-obsolete organic arsenicals are particularly 
toxic to the liver and produce fatty infiltration, central necrosis, and cirrhosis.  
Carcinogenesis 
The association of arsenic exposure and skin tumors was noted more than 100 years ago 
in patients treated with arsenicals. The International Agency for Research on Cancer concluded 
that inorganic arsenic is a skin and lung (via inhalation) carcinogen. Increased risks of other 
cancers, such as kidney and liver cancer, also have been reported, but the association with 
arsenic is not as high as for the tumors just noted. 
Nervous System 
High-dose acute or subacute exposure to arsenic can cause encephalopathy; however, the 
most common arsenic-induced neurological lesion is a peripheral neuropathy with a 
stocking/glove distribution of dysesthesia. This is followed by muscular weakness in the 
extremities, and with continued exposure, deep-tendon reflexes diminish, and muscular atrophy 
follows. The cerebral lesions are mainly vascular in origin and occur in both the gray and white 
matter; characteristic multiple symmetrical foci of hemorrhagic necrosis occur.  
Arsenic-induced neurotoxicity 
Arsenic effects manifest themselves weeks after first exposure as both central and 
peripheral neuropathy. Central neuropathy due to As poisoning has been reported to cause 
impairment to neurological functions such as learning, short-term memory and concentration.65 
People chronically poisoned by arsenic occurring naturally in groundwater may suffer from toxic 
delirium and encephalopathy.66 Neuropsychological tests showed mildly impaired psychomotor 
speed and attentive processes, whereas verbal learning and memory were severely impaired. 
The most frequent neurological manifestation by As is peripheral neuropathy that may 
last for several years or even life-long. The peripheral neuropathy may lead to rapid severe 
ascending weakness, similar to the Guillan-Barré syndrome, requiring mechanical ventilation. 
Peripheral neuropathy is common in persons chronically exposed to As-contaminated drinking 
water.65 
From human clinical cases studied by Le Quesne and McLeod it has become clear that 
As exposure results in a latent reaction to the nervous system, which was established through 
their reduced Nerve Conduction Velocities (NCVs) measurements.33 These patients showed 
some recovery in the years following exposure to As; however, a full NCV regain was not 
achieved. It is doubtful whether PNS symptoms will ever disappear completely. Patients exposed 
to As show significantly lower NCVs in their peripheral nerves incomparison to their 
referents.32,67,48 
Perhaps, changes in cytoskeletal composition may be the major reason of As poisoning 
leading to axonal degeneration, which in turn could lead to axonopathy. An actual mechanistic 
model for arsenic neurotoxicity is as yet not easy to hypothesize, although interference with 
cytoskeletal proteins is a primary consideration. Therefore, one may look for such mechanistic 
parallels in other neurotoxins, especially neurotoxic metals, but also in other neurodegenerative 
diseases. Metals as environmental pollutants such as lead and mercury have been associated with 
Neurodegenerative diseases69 
Exposure to aluminum, lead and mercury are known to have caused abnormalities in the 
nervous system related to interference with the cytoskeleton. Clinically, symptoms may occur as 
peripheral and central neuropathies. Aluminum has been known to cause dialysis encephalopathy 
in some individuals with renal failure. Furthermore, it has been suggested that aluminum might 
be implicated in Alzheimer’s disease (AD), because of some similarities in pathological changes. 
The pathological changes in both cases can be summarized as presence of neurofibrillary tangles 
as diagnostic hallmarks AD.70 
However, further examination of these tangles has shown differences in their tangles 
between AD and the aluminum-exposed patients, in AD patients tangles consist of paired helical 
filaments, whereas those induced by aluminum are single.71 Aluminum exposure in animal 
studies has shown induction of neurofibrillary degeneration. Phosphorylation of cytoskeletal 
proteins appears to modulate their interactions with one another and with other cellular proteins. 
Disruption of the phosphorylation of cytoskeletal proteins results in disorganization of the 
cytoskeletal structure.72 
Other metals as neurotoxicants such as lead have also been indicated in the etiology of 
amyotrophic lateral sclerosis (ALS), whereas manganese has been reported to be involved in 
Parkinson’s disease (PD) or a similar syndrome, Parkinsonism. Exposure to lead has been shown 
to be related to ALS in a case control study conducted in New England from 1993 to 1996.73,74 
Generally, ALS is divided into two forms: (1) the classic sporadic form; (2) the familial, 
presumably hereditary form. The cause of the sporadic form is unknown. The cause of the 
familial form is believed to be genetic, attributable to a mutation in Cu–Zn superoxide 
dismutase.75 
Studies in occupational exposure have suggested an association between PD and elevated 
exposure to manganese.76 Exposure to manganese can cause neurotoxicity and a neurological 
syndrome that resembles PD.77 Neurofilament proteins are major constitutes of neurons and they 
control axonal caliber, transport and signal.78 In neurodegenerative diseases such as AD it 
appears that the metabolism of neurofilaments is disturbed, as indicated by the presence of 
neurofilament epitopes in the neurofibrillary tangles, as well as by the severe reduction of the 
expression of the gene for the light neurofilament subunit of the neurofilament triplet 
(neurofilament High, - Middle and –Light) in brains of AD patients.79 
Accumulation of neurofilaments in the proximal cell body and the perikaryon of motor 
neurons is a hallmark of ALS and PD.75,78 Disruption and disorganization of neurofilament 
transport and neuron cytoskeletal network is a pathological feature seen in all of these 
neurodegenerative diseases. In rats exposed to As , decrease of the neurofilament Light subunit 
(NF-L) in sciatic nerve is evident.80 Arsenic-induced decrease of NF-L may play an important 
role in the pathological changes of the nervous system, since NF-L is the only NF protein 
capable of independently organizing and co-assembling filaments in vivo. Both NF-H and NF-M 
need NF-L protein to form a heteropolymer in the cytoskeletal framework.81 
However, in vitro studies with iAsIII in neuroblastoma (SK-N-SH) and Schwannoma 
(ST-8814) cell lines show no effect on their mRNA expression level of cytoskeletal genes.82 
Thus, it can be suggested that the decrease in NF-L expression is a post-translational activity as a 
result of a proteolytic process. Calpain (calcium-activated cytoplasmic protease) could be 
responsible for NF-L degradation, since neuroblastoma cells (SY-5Y) treated with arsenic 
trioxide (trivalent As) show an increase in intracellular calcium.83 
Studies in PC12 cells under oxidative stress circumstances have shown an increase of 
calcium in the cells and up-regulation of calpain leading to degradation of NF-L protein.84 
Furthermore, inactivation of calpain by calpain inhibitor (MDL-28170) prevents NF-L 
breakdown.85,86 These results suggest that As-induced destabilization and disruption of the 
cytoskeletal framework is partly due to activation of calpain, through influx of Ca2+, which in 
turn is responsible for NF-L degradation in a calcium-induced proteolytic process. 
Another important cytoskeletal protein in neurodegenerative diseases is the tau protein 
(MAPtau), which is a member of the microtubule protein family transcripted by alternative 
splicing of a single gene. It has tandem repeats of a tubulin binding domain and promotes tubulin 
assembly. Although tau proteins are found in all cells, they are major components of neurons 
where they are predominantly associated with microtubules of the axon. Changes in tauprotein 
may play a role in the pathogenesis of neurodegenerative diseases.  
In AD patients, MAP-tau becomes abnormally hyperphosphorylated and accumulates as 
tangles of paired helical filaments in neurons undergoing degeneration. Hyperphosphorylated 
MAP-tau disorganizes microtubules assembly from normal tau and tubulin, which may lead to 
the formation of the neurofibrillary tangles and the degeneration of the affected neurons in AD 
patients. Arsenic may affect the phosphorylation of tau-proteins as well. Giasson et al. 
demonstrated hyperphosphorylation of tau-proteins in Chinese hamster ovary (CHO) cells in 
vitro after treatment with iAsIII.87 
They also showed that iAsIII causes a significant increase in the phosphorylation of 
several amino acid residues in tau. This is in line with experiments in rats with iAsIII, which 
have also shown that the rats’ MAP-tau was hyperphosphorylated after dosing them with iAsIII 
{unpublished data}. These results indicate that As may be involved in the cascade leading to 
deregulation of tau function associated with neurodegeneration. 
 
 
Diagnosis and treatment of Arsenic (As) poisoning 
Arsenic concentration measurements for diagnostic purpose are usually carried out in 
urine. Acute As toxicity is usually diagnosed by increased urinary As in excess of 50 cg/l urine 
sample or 100 cg in 24-hour urine, and a shorter time span before examination, if no seafood has 
been ingested. The urine is collected in metal-free containers. Other biological samples, such as 
blood, and even hair and nails in chronic cases, are also used in the clinical laboratory. For 
treatment of acute As poisoning, the primary concern is to correct the dehydration caused by As 
and restore vital bodily functions.  
In order to increase elimination, physicians prescribe gastric lavage and activated 
charcoal, but haemodialysis may also be considered. The efficacy of these detoxification 
methods, however, has not been well recorded. Although the metalloid As cannot be categorized 
as a metal, it shows some metal properties. Based on this fact, chelators can be used to remove 
As ions from the body. For treatment of acute As poisoning, the chelator 2.3-dimercapto-1-
propanol (British Anti-lewisite, BAL) has been used with successful results.88,67 
Patients who were administered this drug showed elevated As excretion in their urine. At 
follow-up, their urinary As concentration was decreased to the background level. At the moment 
of admittance, neurological examination demonstrated no signs of nervous system depression. 
However, these patients survived the high dose of ingested As with only latent neuropathy 
symptoms. Neurological complications such as distal, symmetrical, sensory, axonal neuropathy 
are late effects of acute As poisoning. These neurological effects are non-responsive to 
chelation.89 
In clinical cases with chronically poisoned patients, trials with 4 As chelators such as 
BAL, meso-2.3-dimercaptosuccinic acid (DMSA), D-penicillamine and sodium 2.3-dimercapto-
1-propamesulfonate (DMPS) did not provide any clinical, biochemical or histopathological 
benefits.68,9092 On the other hand studies done in rats with an As chelator such as BAL showed 
depletion of tissue As and its excretion via urine and faeces.38 Although the binding affinity of a 
chelating agent for the metal is greater than for endogenous ligands, chelating is generally 
ineffective for treating established arsenical peripheral neuropathy.39 
After long-term exposure to arsenic, treatment with dimercaprol and penicillamine also 
may be used, but oral penicillamine alone usually is sufficient. The duration of therapy is 
determined by the clinical condition of the patient, and the decision is aided by periodic 
determinations of urinary arsenic concentrations. Dialysis may become necessary with severe 
arsenic-induced nephropathy; successful removal of arsenic by dialysis has been reported (Vaziri 
et al., 1980). 
Antioxidants are seemingly magical nutrients that can repair cell damage that happens in 
all our bodies over time, including those of our cats. These nutrients occur naturally, common 
antioxidants include vitamin A, vitamin C, vitamin E and certain compounds called carotenoids 
(like lutein and beta-carotene). 
 
 
 
B) IMPORTANCE OF FLAVONOIDS IN OXIDATIVE STRESS 
Flavonoids belong to a group of natural substances with variable phenolic structures and 
are found in most plant species, and account for a significant percentage of the chemical 
constituents of some; e.g. dried green tea leaves contain approximately 30% flavonoids by 
weight.  
Flavonoids have been shown the very good antioxidant activity of flavonoids-their ability 
to scavenge hydroxyl radicals, superoxide anions, and lipid peroxy radicals-may be the most 
important function of flavonoids, and underlie many of the above actions in the body.  
Oxidative damage is implicated in most disease processes, and epidemiological, clinical, 
and laboratory research on flavonoids and other antioxidants suggest their use in the prevention 
and treatment of a number of diseases.  
These natural products were known for their beneficial effects on health long before 
flavonoids were isolated as the effective compounds. More than 4000 varieties of flavonoids 
have been identified.94 
Flavonoids, or bioflavonoids, are a ubiquitous group of polyphenolic substances which 
are present in most plants, concentrating in seeds, fruit skin or peel, bark, and flowers. A great 
number of plant medicines contain flavonoids, which have been reported by many authors as 
having antibacterial, anti-inflammatory, anti-allergic, anti-mutagenic, antiviral, antineoplastic, 
anti-thrombotic, and vasodilator actions.  
The structural components common to these molecules include two benzene rings on 
either side of a 3-carbon ring. 
  Multiple combinations of hydroxyl groups, sugars, oxygen’s and methyl groups attached 
to these structures create the various classes of flavonoids.95 
 
 
 
 
 
 
 
 
 
Classification of flavonoids and their common sources 96,97 
 
Pharmacological effects of Flavonoids   
Antioxidant effect  95 
  Flavonoids have been shown in a number of studies to be very good antioxidants, capable 
of scavenging hydroxyl radicals, superoxide anions, and lipidperoxy radicals. Free radicals, 
including the superoxide radical (O2˙-), hydroxyl radical (.OH), hydrogen peroxide (H2O2) , and 
Chemical 
Class 
Examples Major Dietary Source 
 
Flavonols 
 
Flavanols 
 
 
 
 
 
Flavones 
 
Isoflavones 
 
 
Flavanones 
 
 
Flavanonols 
 
Anthocyan
idins 
Quercetin, Rutin, Myricetin,       
Kaempherol                        
Monomers (Catechins): Catechin, 
Epicatechin, Epigallocatechin  
Epicatechin gallate, Epigallocatechin. 
Dimers and Polymers: Theaflavins,  
Thearubigins, Proanthocyanidins 
 
Apigenin, Chrysin, Luteolin  
 
Genistein, Glycitein, Daidzein, 
Formononetin. 
 
Hesperidin, Narigenin 
 
 
Taxifolin 
 
Cyanidin, Delphinidin, Malvidin, 
Pelargonidin, Peonidin, Petunidin 
Tea, Red wine, Apple, Tomato, 
Cherry and Onion 
Catechins: Tea, chocolate, 
grapes, berries, apples 
Theaflavins, Thearubigins: Tea 
Proanthocyanidins: Chocolate, 
apples, berries, red wine 
 
Thyme and Parsley 
 
Soya bean and other legumes 
 
 
Grapefruit and Orange 
 
 
Lemon and Sour orange 
 
Red, blue, and purple berries; 
red and purple grapes; red wine 
lipid peroxide radicals have been implicated in a number of disease processes, including asthma, 
cancer, cardiovascular disease, cataracts, diabetes, gastrointestinal inflammatory diseases, liver 
disease, macular degeneration, periodontal disease, and other inflammatory processes.  
These radical oxygen species (ROS) are produced as a normal consequence of 
biochemical processes in the body and as a result of increased exposure to environmental and/or 
dietary xenobiotics. ROS are also beneficial components of the immune response, hepatic 
cytochrome P450-mediated detoxification, and regulation of smooth muscle tone. It is an 
imbalance in the oxidant versus antioxidant processes (oxidative stress) that is thought to cause 
the subsequent cellular damage which leads to the disease processes named above.  
The body’s antioxidant systems, including superoxide dismutase, catalase, and 
glutathione, should keep the oxidative processes in check; however, deficiencies of nutritional 
antioxidants (flavonoids; vitamins A, C, E; the minerals selenium and zinc; coenzyme Q10, 
lipoic acid; and L-cysteine), and/or an over whelming oxidant stress can overload this system.16 
The mechanism of free-radical damage includes ROS-induced peroxidation of polyunsaturated 
fatty acids in the cell membrane lipid bilayer, which causes a chain reaction of lipid 
peroxidation, thus damaging the cellular membrane and causing further oxidation of membrane 
lipids and proteins. Subsequently, cell contents, including DNA, are damaged. It is this free 
radical-induced damage which is thought to precede these overt disease processes. 
Anti-atherosclerotic effects 98 
  Because of their anti-oxidative properties, flavonoids are likely to have a major influence 
on the vascular system. Oxygen radicals can oxidize LDLs, which injures the endothelial wall 
and there by promotes atherosclerotic changes. A few clinical studies have pointed out that 
flavonoid intake protects against coronary heart disease, the flavonoids in regularly consumed 
foods might reduce the risk of death from coronary heart disease in elderly men. Oxidative stress 
and vascular damage are postulated to play a key role in dementia; the intake of flavonoids 
appears inversely related to the risk of dementia.  
Anti thrombogenic effects 95 
Platelet aggregation contributes to both the development of atherosclerosis and acute 
platelet thrombus formation, followed by embolization of stenosed arteries. Activated platelets 
adhering to vascular endothelium generate lipid peroxides and oxygen free radicals, which 
inhibit the endothelial formation of prostacyclin and nitrous oxide. Selected flavonoids, such as 
quercetin, kaempferol, and myricetin were shown to be effective inhibitors of platelet 
aggregation.  
Flavonols are particularly antithrombotic because they directly scavenge free radicals, 
thereby maintaining proper concentrations of endothelial prostacyclin and nitric oxide. 
Flavonoids are powerful antithrombotic agents in vitro and in vivo because of their inhibition of 
the activity of cyclooxygenase and lipoxygenase pathways. It is well known that arachidonic 
acid, which is released in inflammatory conditions, is metabolized by platelets to form 
prostaglandin, endoperoxides, and thromboxane A2, leading to platelet activation and 
aggregation.  
The main anti aggregatory effect of flavonoids is thought to be by inhibition of 
thromboxane A2 formation. Flavonoids affect arachidonic acid metabolism in different ways.  
Some flavonoids specifically block cyclooxygenase or lipoxygenase, whereas others block both 
enzymes. In vitro studies showed that flavonoids bind to platelet membranes and may therefore 
have an accumulative effect over time. 
Anti-tumour effects 96 
 Antioxidant systems are frequently inadequate, and damage from reactive oxygen species 
is proposed to be involved in carcinogenesis. Reactive oxygen species can damage DNA, and the 
division of cells with unrepaired or misrepaired damage leads to mutations. Reactive oxygen 
species can interfere directly with cell signalling and growth. The cellular damage caused by 
reactive oxygen species can induce mitosis, increasing the risk that damaged DNA will lead to 
mutations, and can increase the exposure of DNA to mutagens. It has been stated that flavonoids, 
such as antioxidants, can inhibit carcinogenesis. Some flavonoids such as apigenin, fisetin and 
luteolin are stated to be very good inhibitors of cell proliferation. 
Anti-inflammatory effects 
 Cyclooxygenase and lipoxygenase play an important role as inflammatory mediators. 
They are involved in the release of arachidonic acid, which is a starting point for a general 
inflammatory response. Selected phenolic compounds were shown to inhibit the cyclooxygenase 
and 5-lipoxygenase pathways. This inhibition reduces the release of arachidonic acid. Quercetin 
inhibits both cyclooxygenase and lipoxygenase activity, thus diminishing the formation of these 
inflammatory metabolites.  
Another anti-inflammatory feature is that flavonoids also inhibit eicosanoid biosynthesis. 
Eicosanoids, such as prostaglandins, are involved in various immunologic responses. Flavonoids 
also inhibit both cytosolic and membrane tyrosine kinase. Integral membrane proteins, such as 
tyrosine 3-monooxygenase kinase, are involved in a variety of functions, such as enzyme 
catalysis, transport across membranes, and transduction of signals that function as receptors of 
hormones and growth factors, and energy transfer in ATP synthesis.  
Inhibition of these proteins results in inhibition of uncontrolled cell growth and 
proliferation.  Tyrosine kinase substrates seem to play key roles in the signal transduction 
pathway that regulates cell proliferation. Another anti-inflammatory property of flavonoids is 
their suggested ability to inhibit neutrophil degranulation. This is a direct way to diminish the 
release of arachidonic acid by neutrophils and other immune cells.  
Flavonoids inhibit the angiogenesis, which is regulated by a variety of endogenous 
angiogenic and angiostatic factors. Pathologic, unregulated angiogenesis occurs in cancer. 
Angiogenesis inhibitors can interfere with various steps in angiogenesis, such as the proliferation 
and migration of endothelial cells and lumen formation. Flavonoids seem to play an important 
role among the known angiogenesis inhibitors.  
However, the mechanism behind the antiangiogenic effect of flavonoids is unclear. A 
possible mechanism could be the inhibition of protein kinase these enzymes are implicated to 
play an important role in signal transduction and are known for their effects on angiogenesis. 
Very goodial beneficial effects have been elucidated. The flavonoids as natural compounds have 
several great advantages over other therapeutic agents because many diets are rich in 
polyphenolic compounds and are consumed daily having a relatively long half-life with 
minimum side effects.  
 
 
 
Fig. 2. Effect of flavonoids in various diseases99 
       
Effect of flavonoids on diabetes mellitus: 100 
Flavonoids can ameliorate some of the consequences of diabetes mellitus. Flavonoids 
have been identified to be good inhibitors of aldoser-eductase. Effect of flavonoids on diabetes 
mellitus It has been reported by several researchers that quercetin possess anti-diabetic activity 
and it has been found that it brings about regeneration of pancreatic islets and increased insulin 
release in streptozotocin-induced diabetes. It has been reported to stimulate Ca2+ uptake from 
isolated islet cells thus suggesting it to be effective even in non-insulin dependent diabetes. 
Citrus flavonoids:101 
Citrus fruits are well known for providing ample amounts of vitamin C. But they also supply 
bioflavonoids; substances that are not required for life but that may improve health. The major 
bioflavonoids found in citrus fruits are, Diosmin, Hesperidin, Rutin, Naringin, Tangereti,  
Diosmeti,  Narirutin, Neohesperidin, nobiletin and Quercetin. 
Citrus bioflavonoids and related substances are widely used in Europe to treat diseases of 
the blood vessels and lymph system, including hemorrhoids, chronic venous insufficiency, leg 
ulcers, easy bruising, nosebleeds, and lymphedema following breast cancer surgery. These 
compounds are thought to work by strengthening the walls of blood vessels.  
Bioflavonoids are also often said to act as antioxidants. Lemon juice has a high 
antioxidant capacity due to the presence of citrate, vitamin C, vitamin E and flavonoids such as 
eriocitrin, hesperetin102 and limonoid.103 Vitamin E may prevent calcium oxalate crystal 
deposition in the kidney by preventing hyperoxaluria-induced peroxidative damage to the renal 
tubular membrane surface (lipid peroxidation), which in turn can prevent calcium oxalate crystal 
attachment and subsequent development of kidney stones the present compound.104 
Diosmin is a type of citrus bioflavonoid mostly found in citrus fruits often used as a 
dietary supplement. Diosmin is considered to be a vascular-protecting agent used to treat chronic 
venous insufficiency, haemorrhoids, lymphedema, and varicose veins. As a flavonoid, diosmin 
also exhibits anti-inflammatory, free-radical scavenging, and anti-mutagenic properties.105  
Science the previous studies reported citrus flavonoids having anti urolithiatic property, 
antioxidant activity and the present compound is also a citrus flavonoid, we evaluated the effect 
of diosmin anti urolithiatic activity against the ethylene glycol induced Urolithiasis and 
nephroprotective activity against gentamicin induced nephron toxicity on Swiss Albino Wistar 
rats. 
     
                                                
 
 
 
 
 
 
 
 
2. DRUG PROFILE 
Name of the compound: Diosmin 
 Molecular structure of Diosmin:106 
 
Chemical name of Diosmin 
{D,(5-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl] oxymethyl] oxan-2-yl]oxychromen-4 
one)}  
Molecular formula :  C28H32O15 
Molecular weight :  608.54 
Melting point  :   278-270°C 
Storage temperature :  2-8°C 
Physical Appearance :  Light yellow to brown yellow powder. 
Solubility  :  Insoluble in water and alcohol, Dissolves in dilute alkali  
hydroxides, and DMSO (50mg/ml). 
Description 
Diosmin is greyish-yellow or light yellow hygroscopic powder, practically insoluble in 
water, soluble in dimethyl sulphoxide, practically insoluble in alcohol. It dissolves in dilute 
solutions of alkali hydroxides. 
 Dosage 
The standard dose of diosmin is 500 mg/day maximum recommended duration of usage 
was 3 months. Diosmin is a semisynthetic phlebotropic drug, a member of the flavonoid family, 
a naturally occurring flavone glycoside, used in the treatment of venous disease, i.e., chronic 
venous insufficiency (CVI) and hemorrhoidal disease (HD), in acute or chronic hemorrhoids, in 
place of rubber-band ligation, in combination with fiber supplement, or as an adjuvant therapy to 
haemorrhoidectomy, in order to reduce secondary bleeding. Reduce capillary permeability and to 
have anti-inflammatory action were collectively known as vitamin P, but these substances, 
however, are not vitamins. 
Diosmin was first isolated in 1925 from Scrophularia nodosa, and first introduced as a 
therapeutic agent in 1969. Diosmin differs molecularly from hesperidin by the presence of a 
double bond between two carbon atoms in diosmin central carbon ring. Diosmin can be 
manufactured by extracting hesperidin from citrus rinds, followed by conversion of hesperidin to 
diosmin. Diosmin has been used for more than 30 years as a phlebotonic and vascular-protecting 
agent, and has recently begun to be investigated for other therapeutic purposes, including cancer, 
premenstrual syndrome, colitis, and diabetes.105 
Biochemistry and Pharmacokinetics 
Flavonoids are a large group of plant pigments sharing the same basic chemical structure; 
i.e., a three-ringed molecule with hydroxyl (OH) groups attached. Diosmin (C28H32O15) occurs 
naturally as a glycoside, meaning it has a sugar molecule attached to its three-ringed flavonoid 
structure. 
Pharmacokinetic investigations have shown diosmin is rapidly transformed by intestinal 
flora to its aglycone form, diosmetin. Diosmetin is absorbed and rapidly distributed throughout 
the body with a plasma half-life of 26-43 hours. Diosmetin is degraded to phenolic acids or their 
glycine-conjugated derivatives and eliminated through the urine. Diosmin or diosmetin not 
absorbed is eliminated in the feces.107,108 
 
 
 
Clinical Indications 
Varicose Veins/Chronic Venous Insufficiency 
Chronic venous insufficiency is characterized by pain, leg heaviness, a sensation of 
swelling, and cramps, and is correlated with varicose veins. Diosmin-containing flavonoid 
mixtures have also been effective in treating severe stages of chronic venous insufficiency, 
including venous ulceration and delayed healing.109  
Cancer 
Diosmin has been investigated in a number of animal models and human cancer cell 
lines, and has been found to be chemo preventive andantiproliferative.110 
Lymphedema 
Diosmin acts on the lymphatic system by increasing lymph flow and lymph oncotic 
pressure. Flavonoid mixture containing diosmin was used to treat upper limb lymphedema 
secondary to conventional therapy for breast cancer. Results showed improvement of symptoms 
and limb volume; the mean decrease in volume of the swollen limb reached 6.8 percent. In 
addition, lymphatic functional parameters assessed with scintigraphy were significantly 
improved. Animal studies of high-protein lymphedema, such as in burns and lung contusions, 
showed significant improvement with diosmin.111 
Diabetes 
Diosmin has been shown to improve factors associated with diabetic complications. 
Blood parameters of glycation and oxidative stress were measured in type 1 diabetic patients 
before and after intervention with a diosmin-containing flavonoid mixture. A decrease in 
haemoglobin A1C was accompanied by an increase in glutathione peroxidase, 18 demonstrating 
long-term decreased blood glucose levels and increased antioxidant activity. 
Diosmin can normalize capillary filtration rate and prevent ischemia in diabetics. 
Rheological studies of type 1 diabetics show diosmin can facilitate hemorheological 
improvements due to decreased RBC aggregation, which decreased blood flow resistance, 
resulting in reduction of both stasis and ischemia.112 
 
Haemorrhoids 
Several large clinical trials have demonstrated diosmin to be effective in the treatment of 
acute and chronic symptoms of hemorrhoids. 
Other clinical indications 
Studies have also investigated the use of diosmin for stasis dermatitis, wound healing, 
premenstrual syndrome, mastodynia, dermato fibro sclerosis, viral infections, and colitis. More 
clinically oriented research is indicated.105 
Drug - Nutrient Interactions 
Diosmin can cause a decrease in RBC aggregation and blood viscosity. There are no 
documented cases of adverse interactions between diosmin and prescription medications, but 
caution should be taken when combining diosmin with aspirin or other blood-thinning 
medications. Data suggest that diosmin has an inhibitory effect on cytochrome P450 mediated 
metabolism in healthy volunteers, which may alter the pharmacokinetics of drugs taken 
concomitantly.  
Side Effects and Toxicity 
In animal studies, a flavonoid mixture containing 90 percent diosmin and 10 percent 
hesperidin had an LD50 of more than 3g/kg. In addition, animal studies have shown the absence 
of acute, sub-acute, or chronic toxicity after repeated oral dosing for 13 and 26 weeks using a 
dose representing 35 times the recommended daily dose. Diosmin is considered to have no 
mutagenic activity, embryo toxicity, nor any significant effect on reproductive function. Tran’s 
placental migration and passage into breast milk are minimal.113 
 
3. AIM AND OBJECTIVE 
The term ‘neurotoxic’ is used to describe a substance, condition or state that damages the 
nervous system and/or brain, usually by killing neurons. Arsenic is a semi-metalloid and 
exposure to As is a worldwide health problem causing various disorders and diseases in millions 
of people around the world. Arsenic causes various diseases such as numerous organ cancers and 
also patients show severe effects on their nervous system. However, the mechanisms of As 
neurotoxicity remain somewhat obscure while the instance of As exposure remains a prevalent 
human health concern.114 
Diosmin is a semisynthetic flavone derivative of hesperidin occur naturally in citrus 
fruits. The drug is widely used in treatment of varicose veins and venous ulcers, lymphatic 
insuffi ciency and hemorrhoids. In these conditions, Diosmin exerts a venotonic action, 
decreasing venous reflux, and thereby alleviating edema and providing effective venous 
drainage.115 
Moreover, the drug has been shown to provide better outcomes for patients with impaired 
cardiac function before undergoing cardiac operations that require cardiopulmonary bypass. 
These effects of Diosmin can be ascribed to the antiinflammatory, microcirculatory, and 
antioxidant effects of its flavonoid substances. In this context, Diosmin has been shown to 
decrease the levels of granulocyte and macrophage infi ltration into the infl amed tissues as well 
as leucocyte adhesion to the vascular endothelium.  
The decrease in release of oxygen free radicals, cytokines, and proteolytic matrix 
metalloproteinases from activated infl ammatory and endothelial cells, results in lower levels of 
inflammation, decreased microvascular permeability and decreased leukocyte-dependent 
endothelial damage. Diosmin decreases vascular permeability more than any of its single 
constituents, suggesting that the flavonoids present in its formulation have a synergistic action.  
The drug possesses an antioxidant effect, significantly decreasing the level of hydroxyl 
free radicals, increasing free SH-group concentration, and natural scavenger capacity.115 
The effects of arsenic on nervous system have received considerably less attention. In this 
study we planned to investigate the effects of Arsenic trioxide on the oxidative stress, contents of 
lipids, proteins, antioxidant defence systems in various regions of the rat brain to seek 
contribution of arsenic, if any, in peroxidative damage and other neurochemical perturbations. 
Furthermore, to unravel the effects of recovery on arsenic induced neurotoxicity in various 
regions of the rat brain. 
The present study attempts to screen the arsenic poisoning particularly the role of 
oxidative stress in the toxic manifestation, an attempt for the treatment and a possible beneficial 
role of antioxidants supplementation to achieve the optimum effects in wistar rats. 
The present work, evaluation of Diosmin against Arsenic induced neurotoxicity was 
planned with the following objectives: 
 To determine the effect of Diosmin on plasma concentrations of total proteins, albumin, 
glucose, urea, creatinine and bilurubin 
 To evaluate Diosmin on the plasma levels of total lipids, cholesterol, triglycerides, HDL-
C, LDL-C and VLDL-C 
 To study the effect of Diosmin on concentrations of brain and serum Acetylcholinesterase 
levels 
 To determine the effect of Diosmin on Biogenic amines of Corpus striatum, Frontal 
cortex and Hippocampus in Arsenic trioxide induced neurotoxicity in rats 
 Dopamine 
 Epinephrine 
 Norepinephrine 
 Serotonin 
 3,4-Dihydroxy phenylacetic acid 
 Homovanilin acid 
 To evaluate the effect of Diosmin on Brain tissue Antioxidants in Arsenic trioxide 
induced neurotoxicity in rats 
 Lipid peroxidation 
 Superoxide dismutase 
 Catalase 
 Reduced Glutathione 
 Histopathological evaluation of brain tissues of rats to evident the neuroprotective nature 
of  Diosmin 
 
 
 
 
4. REVIEW OF LITERATURE 
(Yusuf T et al., 2013) Liver ischemia reperfusion injury (IRI) is an important pathologic 
process leading to bodily systemic effects and liver injury. It has been found that preoperative 
and intraoperative diosmin treatment decreases cellular damage and protects cells from toxic 
effects in liver IRI. Diosmin may be used as a protective agent against IRI in elective and 
emergent liver surgical operations.116 
(Thiruvengadan Devaki et al., 2013) Hepatic steatosis  is  obesity  related  metabolic 
disorder  characterized  by  aggregation  of  fat  droplets  and  its  regulation  is currently being 
warranted. Disomin was reported to exert antioxidant, anti-mutagenic, anti-hypertensive actions.  
In  this  study ,  we  have  analyzed  the  role  of  diosmin  in regulating  triglyceride  
accumulation  during  high-carbohydrate  diet  (HCD)-induced  hepatic  steatosis  and  
acknowledged  its role.117 
(Ivan V. Batchvarov et al., 2010) Chronic  venous  insufficiency  (CVI)  is  increasingly 
affecting  more and  more patients,  usually  in  their  prime  of life. Patients  in  all  phases  of  
CVI demonstrated  good  tolerance  to  the  Diosmin,  which  was  found to have the best effect 
in reducing   the edema in patients  with initial  symptoms.  It  also  had  a very  good  effect  on  
pain  intensity  in  patients  feeling  heaviness  and  continuous  pains  in  the lower  legs  in  
walking.118 
(Sergeeva E.О et al., 2011) Hesperidin, diosmin and detraleks demonstrate significant 
hepatoprotective effect in health-care use in the effective dose  against  the  acute  toxic  liver  
injury  CCI4  ,  more  effective  than  the  reference  drug  effects  such  CARS ekivalentnoy  
dose.  The  combination  of  diosmin  and  hesperidin  9:1,  as  in  the  preparation  "Detralex"  
leads  to increased hepatoprotective effect. It can be assumed that the vascular effects, which 
have hesperidin,diosmin and detraleks, such as, improved microcirculation and metabolism of 
the vascular wall, are also of great importance for the manifestation of their hepatoprotective 
activity.119 
(Maksimovic ZV et al.,) Chronic venous insufficiency (HVI) is manifested by the 
progressive signs of venous stasis. This disorder is treated by: compressive bandaging, 
medicaments, sclerotherapy, surgery, etc. in a prospective study administration of semisynthetic 
diosmin during 30 days results in significant improvement of clinical signs, quality of life and 
CEAP stage of HVI.120 
(Takuji Tanaka et al., 1997) The modifying effects of flavonoids diosmin and hesperidin 
during the initiation and post-initiation phases of oesophageal carcinogenesis initiated withN-
methyl-N-amylnitrosamine (MNAN) were investigated in male Wistar rats. Findings from the 
study suggest that Diosmin and hesperidin supplementation, individually or in combination, was 
effective in inhibiting the development of oesophageal cancer induced by MNAN when given 
during the initiation phase, and such inhibition might be related to suppression of increased cell 
proliferation caused by MNAN in the oesophageal mucosa.121 
(Leelavinothan Pari et al., 2010) In the investigation of the effect of diosmin on hepatic 
key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats, 
Diosmin was administered to streptozotocin-induced (45 mg/kg b.w) diabetic rats at different 
doses (25, 50, 100 mg/kg b.w) for 45 days. The activities of the hepatic key enzymes such as 
hexokinase and glucose-6-phosphate dehydrogenase were significantly increased whereas, 
glucose-6-phosphatase and fructose-1,6-bisphosphatase were significantly decreased. 
Furthermore, protection against body weight loss of diabetic animals was also observed. These 
results showed that diosmin has potential antihyperglycemic activity in streptozotocin-
nicotinamide-induced diabetic rats.122 
(Jean-Pierre Savineau et al., 1994) The effect of diosmin, a flavone derivative, on the 
Ca2+ sensitivity of the venous contractile apparatus was investigated in chemically (P-escin) 
skinned strips from the rat isolated femoral vein. Diosmin (0.5-1I0 gM) shifted the 
concentration-response curve to Ca2" (0.05- 5 gM) to the left. The maximal effect was observed 
in the presence of 1 J.M diosmin which increased the contractile response evoked by 0.151iM 
Ca2` from 26.3% to 78.9% of the maximal Ca2+-induced response. This work demonstrates that 
the venotonic action of diosmin involves an increase in the Ca2+ sensitivity of the contractile 
apparatus. Such a mechanism of action could represent a new and important means of 
therapeutic control of vasomotor activity.123 
(Nuria Alvarez et al., 2008) Melanoma is the most important skin cancer in terms of 
mortality, besides developing metastasis in about a third of the patients. Interferon-alpha (IFN-a), 
a highly toxic cytokine, tends to be one of the most important treatments for melanoma. Much 
effort is being directed at obtaining less-toxic antitumoral compounds, particularly natural 
compounds such as flavonoids. In the study of combined treatment of metastatic lung melanoma 
with IFN-a and diosmin in a murine model, IFN-a showed a dose dependent anti-invasive and 
anti proliferative activity in our study, while diosmin showed an anti-invasive activity similar to 
the lower dose of IFN-a used. However, the most relevant result was the synergistic 
antiproliferative effect shown by the combination of the flavonoid and the lowest dose of IFN-a, 
which was similar to that produced by the highest dose of the cytokine alone.124 
(Leelavinothan Pari et al., 2012) Oxidative stress has been suggested as a contributory 
factor in development and complication of diabetes. In the study of evaluation of effect of 
diosmin (DS) in oxidative stress in streptozotocinnicotinamide (STZ-NA)-induced diabetic rats 
by measuring the lipid peroxidation (LPO) as well as the ameliorative properties, oral treatment 
with DS (100 mg/kg/day) for a period of 45 days showed significant ameliorative effects on all 
the biochemical parameters studied. Biochemical findings were supported by histological 
studies. These results indicated that DS has potential ameliorative effects in addition to its 
antidiabetic effect in type 2 diabetic rats.125 
(Xingwei Wu et al., 2013) In the evaluation of retinal microvascular protective effect of 
diosmin in a model of ischemia/reperfusion injury, maintenance of tight junctions integrity and 
reduced permeability of capillaries as well as improvements in retinal edema were observed with 
diosmin treatment, which may contribute to preservation of retinal function. This protective 
effect of diosmin may be at least partly attributed to its ability to regulate the VEGF/PEDF 
ratio.126 
(Hye Hyun Yoo et al., 2007) Diosmin is one of the main components in citrus fruits, and 
the intake of food supplements containing this compound may potentially increase the absorption 
of drugs able to act as P-gp substrates.127 
(Anne M. Melin et al., 1996) In the study of comparision of protective effect of a 
flavonoid, the 3’,5,7-trihydroxy- 4’-methoxyflavone 7-rutinoside or diosmin, on liver 
microsomal lipid peroxidation induced in rats by ei- ther carbon  tetrachloride or carrageenan, 
results suggest that the effect of diosmin differs with the choice of chemical product used; it 
seems a better antioxidant against products inducing inflammation.128 
(Ali Noorafshan et al., 2013) In the investigation of evaluation of the effect of Diosmin 
on renal tissue protection in rats with ethylene glycol-induced nephrolithiasis, Diosmin reduces 
CaOx deposition and the degeneration of glomeruli and tubules.129 
(Martínez1 C et al., 2005) In the study of effect of different phenolic compounds and red 
wine on pulmonary metastatic melanoma, Diosmin revealed the greatest reduction in pulmonary 
metastases, both at the macroscopic and microscopic levels.130 
(Alptekin Yasım et al., 2010) In  the investigation of the  effect  of  diosmin-hesperidin 
combination  treatment  on  serum  lipid  profile  and  oxidativeantioxidative system in high-
cholesterol diet-fed rats, positive changes occurred in oxidative-antioxidative balance and 
administration of diosmin-hesperidin significantly increased the levels of GPX and SOD.131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. MATERIALS AND METHODS 
Experimental Animals 
Male Swiss Albino Wistar rats, weighing 150-180 g were obtained from central animal 
house of Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode, Namakkal 
Dt, Tamilnadu. The animals were acclimatized for 2 weeks in the laboratory conditions before 
experiment. Throughout the acclimatization and experimental period, the animals were housed in 
autoclavable polypropylene cages (six rats per cage) in standard laboratory conditions (humidity 
50–60%, lighting conditions (12-h light/12-h dark cycle) and temperature 21±20C). Rats were 
provided with standard pellet diet and water ad libitum freely throughout the study. Study 
protocol was approved by Institutional Animal Ethical Committee (IAEC), Swamy 
Vivekanandha College of Pharmacy (proposal No.SVCP/IAEC/M.Pharm/03/2013) and 
conducted in accordance with guidelines set by the CPCSEA (Committee for the Purpose of 
Control and Supervision of Experiment on Animals). 
DRUGS 
• Diosmin (Sigma-Aldrich Chemicals Pvt. Ltd., Bangalore, India) 
• Arsenic Trioxide (Mumbai Chemicals Incha Pvt. Ltd., Mumbai, India) 
Experimental Procedure 
Administration schedule of Arsenic Trioxide and Diosmin 
Total of 24 animals obtained were divided into four groups, where each group under-
went different treatment protocol. All animals had free access to regular rat chow and drinking 
water ad libitum for 30 days.132 
In each major group the treatment schedule for subgroups follows as below 
Both ATO and Diosmin were administered individually using water as vehicle (Vol 0.5 ml p.o.) 
 Group 1: Normal control (N = 6, receives vehicle alone) 
 Group 2: Receives Arsenic trioxide 5 mg/kg/day p.o. (N = 6) 
 Group 3: Receives Arsenic trioxide 5 mg/kg p.o. + Diosmin 50 mg/kg p.o. (N = 6) 
 Group 4: Receives Arsenic trioxide 5 mg/kg p.o. + Diosmin 100 mg/kg p.o. (N = 6) 
Collection of blood samples 
Rats of each group were euthanized at the end of treatment period. Blood samples were 
collected from retro orbital venous plexus of rats and placed immediately on ice. Heparin was 
used as an anticoagulant and plasma samples were obtained by centrifugation at 860g for 20 min 
and stored at -60 0C till measurements. Brain was immediately removed; weighed and washed 
using chilled saline solution. Tissues were minced and homogenized (10%, w/v), separately, in 
ice-cold 1.15% KCl–0.01 M sodium, potassium phosphate buffer (pH 7.4) in a Potter–Elvehjem 
type homogenizer. The homogenate was centrifuged at 10,000g for 20 min at 4 0C, and the 
resultant supernatant was used for enzyme assays. Stored plasma samples were subjected for 
biochemical analysis. 
BIOCHEMICAL PARAMETERS 
Estimation of Plasma biochemistry Lipids and Lipoproteins 
1) Estimation of creatinine in plasma 
In this study the modified Jaffe’s method was used to estimate the creatinine level in 
plasma.133 
Principle 
        Creatinine reacts with picric acid to produce a collared compound, creatinine alkaline 
picrate. The change in absorbance is proportional to the creatinine concentration. 
Procedure 
 
Pipette into tubes marked Standard Sample 
Working reagent 
Standard 
Sample 
1000µL 
100µL 
- 
1000µL 
- 
100µL 
Mix and read the optical density (T1) 60 seconds after the sample or standard addition 
exactly 60 seconds after the first reading take second reading (T2) 
2) Estimation of urea in plasma 
In this study enzymatic method is used to estimate the urea level in urine and plasma.134 
Principle 
          Urease splits urea into ammonia and carbon dioxide. Ammonia released in this reaction 
reacts with hypochlorite and phenolic chromogen to produce green colour. The absorbance of 
this green colour at 578 nm (570-620) is directly proportional to the concentration of urea in 
specimen. 
Procedure 
Pipette into tubes marked Urine/plasma Standard Blank 
Working reagent 
Enzyme solution 
Chromogen solution 
0.01 ml 
1.0 ml 
1.0 ml 
0.01 ml 
1.0 ml 
1.0 ml 
- 
1.0 ml 
1.0 ml 
Mix and incubate for three minutes at 37°C for 5 minutes. After completion of incubation 
measure the absorbance of assay mixture against blank at 578 nm.  
 
3) Total protein content in serum 135 
Total protein in serum was measured according to Lowery method as modified by 
Pomory. 
Principle 
The principle behind the Lowery method lies in the reactivity of the peptide nitrogen(s) 
with the copper (II) ions under alkaline conditions which gives a deep blue colour. In addition, 
subsequent reduction of the folin- ciocalteu phosphomolybdic phosphotungustic acid to 
heteropolymolybdenum blue by the copper-catalyzed oxidation of aromatic acids Thus, 
producing intense blue-green colour which was measured calorimetrically at 660 nm.   
 
 
 
Method 
• 1 ml was diluted to 100 ml with 0.1 N NaOH.   
• 0.5 ml of plasma, standard protein and 0.1 N NaOH each were pipette out into test tubes 
labelled ‘Test’, ‘Std’ and ‘Blank’ respectively.   
• 5 ml copper-tartarate-carbonate solution was added to each tube, agitated for a few 
seconds and allowed to stand for 10 min.   
• 0.5 ml of 1 N Folin-ciocalteu reagent was then added to all tubes and mixed vigorously 
allowed standing for 2 h.   
• Optical density of intense blue colour produced was measured calorimetrically at 560 nm 
with UV-Visible spectrophotometer 
4) Estimation of Total cholesterol  
Method: Chod-Pod/ Phosphotungstate Method 136 
Principle: 
Cholesterol   +      H2O       CHE  Cholesterol  + Free fatty acid 
 Cholesterol  +       O2        CHOD Cholest - 4ene 3-one + H2O2 
H2O2 + Phenol + 4-amino antipyrine      POD      4H2O+ Red Quinoneimine complex      
CHE – cholesterol esterase 
CHOD – cholesterol oxidase 
Reagents composition 
1.Cholesterol reagent 
1 Cholesterol esterase (pancreatic) >200 IU/L 
2 Cholesterol oxidase(microbial) >150 IU/L 
3 Peroxidase (horseradish) >2000 IU/L 
4 Sodium phenolate 20 m mol/L 
5 4-amino antipyrine 0.5 m mol/L 
6 Phosphate buffer 68 m mol/L 
7 Lipid clearing agent ------ 
 
2. Cholesterol standard   - 200 mg/dl (5.14 mmol/L) 
Assay and procedure 
Fresh clear and unhaemolysed serum was used for the estimation. 
Assay parameters 
                 Mode            Kinetic 
Wavelength(1nm) 505nm 
Wavelength (2nm) 670nm 
Sample volume 10/20µl 
Reagent volume 500/1000µl 
Incubation time 10 
Incubation temperature 37oC 
Normal low 140 
Normal High 250 
Linearity low 0 
Linearity high 600 
Conc. of standard 200 
Blank Reagent 
Absorbance limit 0.4 
Units mg/dl 
 
Assay Procedure 
Pipette into tubes marked Blank  Standard  Test  
Serum/plasma                 -           - 20µl 
Cholesterol standard              - 20 µl          - 
cholestrol reagent 1000 µl 1000 µl 1000 µl 
 
Mixed well and incubated for 5 min at 37°C or 10 min at room temperature then the samples 
were analyzed in semi auto analyzer. 
5) Estimation of TG (Triglycerides) 136 
Method: (GPO-trinder method)  
Principle: 
Triglycerides +    H2O  Lipases           Glycerol + fatty acids 
Glycerol +ATP GPO         Glycerol – 3-phoshate (G-3-P) + ADP
 
G-3-P + O2 GPO           Dihydroxy acetone phosphate+H2O2 
H2O2  + 4-amino antipyrine + 3,5 – DHBS Peroxidase Quinoneiminedye  + H2O 
GPO – Glycerol phosphate oxidase 
DAP – Dihydroxyacetone phosphate 
DHBS – 3,5-dichloro-2-hydroxybenzene sulfonate 
Reagents composition 
1.Triglycerides des reagent 
s.no Active ingredient Concentration 
1 ATP 2.5 m mol/L 
2 Mg2+ 2.5 m mol/L 
3 4-amino antipyrine 0.8 m mol/L 
4 3-5 DHBS 1 m mol/L 
5 Peroxidase >2000 IU/L 
6 Glycerol kinase >550 IU/L 
7 GPO >8000 IU/L 
8 Lipoprotien lipase >3500 IU/L 
9 Buffer (pH 7.0± 0.1 at 200C 53 m mol/L 
Also contains non-reactive filers, stabilisers and surfactants. 
 
Triglycerides standard - 200 mg/dl (2.3 m mol/L) 
Assay parameters: 
Mode  Kinetic 
Wavelength(1nm) 505nm 
Wavelength (2nm) 670nm 
Sample volume 5/10 
Reagent volume 500/1000 
Incubation time 10min 
Incubation temperature 37 
Normal low 25 mg/dl 
Normal High 160 mg/dl 
Linearity low 0 mg/dl 
Linearity high 900mg/dl 
Conc. of standard 200mg/dl 
Blank Reagent 
Absorbance limit 0.4 
Units mg/dl 
Procedure 
Pipette into 3 test tubes labeled blank (B), standard(S), and total cholesterol (Tc) as 
shown below. 
Pipette into tube marked Blank Standard Test 
Working  Reagent  1000 µl 1000 µl 1000 µl  
Standard - 10 µl - 
Specimen - - 10µl 
 
Mixed well and incubated for 10 minutes at 370 c   or 15 min at room temperature then the 
samples were analyzed in semi auto analyzer. 
 
6)  Estimation of HDL (High density lipoproteins) 136 
Principle 
Serum     phosphotunstate HDL + LDL +VLDL + Chylomicrons  
On addition of precipitating reagent to the serum, followed by centrifugation, HDL 
fraction remains in the supernatant while the lipoproteins precipitate out.   
Reagents composition 
1. Precipitating reagent 
1 Phoshotunstic acid 2.4 m mol/L 
2 Magnesium chloride 40 m mol/L 
2. HDL cholesterol standard – 25 mg/dl. 
Assay and procedure 
Fresh clear and unhaemolysed serum was used for the estimation 
Assay parameters 
For estimation with cholesterol reagent 
Mode End Point 
Wavelength(1nm) 505nm 
Wavelength (2nm) 670nm 
Sample volume 25/50µl 
Reagent volume 500/1000µl 
Incubation time 10 min 
Incubation temperature 370C 
Normal low 30mg/dl 
Normal High 80mg/dl 
Linearity low 0mg/dl 
Linearity high 125mg/dl 
Conc. of standard 25mg/dl 
Blank Reagent 
Absorbance limit 0.3 
Units mg/dl 
 
 
Procedure 
Step1:  Pipette into the centrifuge tube. 
Serum / plasma 0.2 ml 
Precipitating reagent (3) 0.3 ml 
Mixed well and allowed standing at room temperature for 5 min. Centrifuged at 3000 
rpm for 10 min to get a clear supernatant. If supernatant is not clear (high TGL level) dilute the 
sample 1:1 normal saline and multiply the result with 2.  
Step 2: Pipette into 3 test tubes labeled blank (B), standard (S), HDL cholesterol (TH) as 
shown below. 
Pipette into tube 
marked 
Blank Standard Test 
Working  Reagent  1000 µl 1000 µl 1000 µl  
Standard - 50 µl - 
Supernatant - - 50µl 
Mixed well and incubated for 5 min at 37°C or 10 min at room temperature then the 
samples were analyzed in semi auto analyzer. 
7)  LDL cholesterol = Total cholesterol–(HDL cholesterol + TG/5) 
8)  VLDL cholesterol= TG/5 
In vivo antioxidant parameters 
Preparation of homogenate 
Procedure 
 Brains were excised and chopped with surgical scalp into fine slices and were chilled in 
the cold 0.25 M sucrose, quickly blotted with filter paper. The tissue was minced and 
homogenized in ice cold 10 mM tris HCl buffer (to pH 7.4) at a concentration of 10% (w/v) with 
25 stokes of tight teflon pestle of glass homogenizer at a speed of 2500 rpm. The prolonged 
homogenization under hypotonic condition was designed to disrupt as far as possible the 
ventricular structure of cells so as to release soluble protein and leave only membrane and non-
vascular matter in a sedimentable form. It was then centrifuged at 5000 rpm at 20o C temperature 
and clear supernatant was separated and used to estimate reduced glutathione (GSH), catalase 
(CAT) and lipidperoxidation (LPO). 
1) Estimation of Lipid peroxidation 137 
Lipid peroxidation was determined by the method of Slater and Sawsyer et al., 1971. The 
large number of polyunsaturated fatty acids (PUFA’s) makes cell membranes particularly 
vulnerable to lipid peroxidation. The oxidation of PUFA causes them to be more hydrophilic, 
thereby altering the structure of membrane with resultant changes in fluidity and permeability. 
Lipid peroxidation can inhibit the function of membrane bound receptors and enzymes. The 
thiobarbituric acid reacting substance (TBARS) assay is used as an indicator of lipid 
peroxidation and levels of free radicals (Sun and Chen, 1998). 
Reagents  
1. Thiobarbituric acid: 0.67% w/v in 1M tris hydrochloride pH 7, 0.67 g of thiobarbituric acid  
 was dissolved in 100 ml of distilled water. 
2. Trichloroacetic acid (20% w/v): 20 g of TCA was dissolved in 100 ml of distilled water. 
3. Standard malondialdehyde (0-25 n.mol) 
A stock solution containing 50 mm/ml of 1, 1, 3, 3 - tetra ethoxy propane in tris 
hydrochloride buffer in pH -7, 10 ml of stock solution was diluted to 100 ml to get a working 
standard 50 nm malondialdehyde/ml. This was used for preparation of calibration curves. 
 
Procedure 
2 ml of sample was mixed with 2 ml of 20% TCA and kept in ice for 15 min. The 
precipitate was separated by centrifugation and 2 ml of samples of clear supernatant solution 
were mixed with 2 ml aq. 0.67% TBA solution. This mixture was heated on a boiling water bath 
for 10 min. It was cooled in ice for 5 min and absorbance was read at 535 nm. The values were 
expressed as nm of MDA formed/mg of protein values are normalized to protein content of 
tissues. 
 Y – Absorbance differences of final (after 3 min) and initial reading of test sample. 
2) Superoxide dismutase 138  
The SOD activity in supernatant was measured by the method of Misra and Fridovich. 
Superoxide dismutase is an important endogenous antioxidant and prevents production of free 
radicals. It is derived from various sources at different stages of reperfusion (Chaudhary G et al., 
2003). 
Reagents 
1. Carbonate buffer (100mM, pH 10.2) 
2. Epinephrine (3mM) is prepared by reconstituting one vial with 1.0 mL of distilled or 
deionized water. Mix gently until completely dissolved. 
Procedure 
The supernatant (500 µl) was added to 0.800ml of carbonate buffer (100mM, pH 10.2) 
and 100 µl of epinephrine (3mM). The change in absorbance of each sample was then recorded 
at 480 nm in spectrophotometer for 2 min at an interval of 15 sec. Parallel blank and standard 
were run for determination SOD activity. 
One unit of SOD is defined as the amount of enzyme required to produce 50% inhibition 
of epinephrine auto oxidation. 
 
Reagents 
 
Uninhibited(Standard) 
 
Inhibited(Sample) 
 
Blank 
Carbonate buffer 0.900 ml 0.800 ml 1.0 ml 
Supernatant __ 0.1 ml __ 
Epineprine 0.1 ml 0.1 ml __ 
 
The reaction mixtures are diluted 1/10 just before taking the readings in 
spectrophotometer. 
 
 
Calculation 
 
 
 
Where A = Absorbance, Vt = total volume, Vs = sample volume. 
 
3) Reduced glutathione (GSH) 139 
Reduced glutathione was determined by the method of Moran et al.,1979. Normally, the 
brain maintains a high ratio of GSH for antioxidant defense. Depletion of total glutathione and a 
decreased GSH are markers for oxidative stress in ischemic brain (Park et al., 2000). 
Reagents 
1. TCA (10% w/v) solution: Accurately weighed 10 g of TCA was dissolved in    100 ml of 
distilled water. 
2. Phosphate buffer (0.2 M, pH 8) 
3. DTNB reagent (0.6 M): 60 mg of 5,5-dithio bis (2-nitro benzoic acid) was dissolved in 100 
ml of 0.2 M sodium phosphate (pH 8). 
4. Standard glutathione: Prepared by dissolving 10 mg of reduced glutathione in 100 ml of 
distilled water. 
 
 
 
Procedure 
To 1 ml of sample, 1 ml of 10% TCA was added. The precipitated fraction was 
centrifuged and to 0.5 ml supernatant, 2 ml DTNB was added. The final volume was made up to 
3 ml with phosphate buffer. The colour developed was read at 412 nm. The amount of 
glutathione was expressed as µg of GSH/mg protein reduced glutathione was used as standard 
(100 µg/ml). 
 
Y – Absorbance of test sample. 
4) Catalase (CAT)  
Catalase was estimated by the method of Hugo E. Aebi method: hydrogen peroxide: 
hydrogen-peroxidoreductase. Catalase decomposes hydrogen peroxidase and converts it to water 
and diatomic oxygen, whereas superoxide dismutase generates H2O2 from free radicals. An 
increase in production of superoxide dismutase without a subsequent elevation of catalase leads 
to the accumulation of hydrogen peroxidase, which is converted to hydroxyl radicals that 
produced deleterious effect on brain (Pigeolet, 1998). 
 
Principle 
In UV range H2O2 can be followed directly  by the decrease in absorbence (O.D 240) per 
unit time is measure of catalase activity.  
H2O2                                  H2 + O2 
RDOH                                H2O + ROH + A 
Decomposition of H2O2 = Decrease in absorbance at 240 nm  
Reagents 
1. Phosphate buffer (50 mM, pH 7.0) 
A. Dissolve 6.81 g KH2PO4 in distilled water and make up to 1000 ml. 
B. Dissolve 8.9 g NaH2PO4. 2H2O in distilled water and make up to 1000 ml. 
Mix the solution A and B in proportion 1:15 (v/v) 
2. Hydrogen peroxide (30 mM/I): Dilute 0.34 ml of 30% Hydrogen peroxide with phosphate 
buffer up to 100 ml. 
Procedure 
Dilute homogenate 20 times with Phosphate buffer pH 7.0 
 
Calculation 
Log (A / B) × 2297.3 
Where, A: Initial absorbance             
B:  final absorbance (after 30 second)  
Units = µ moles of H2O2 consumed/min/mg 
Histopathological studies 
For Histopathological studies, brain tissue was obtained from the excised brain and was 
immediately fixed in 10% buffered neutral formalin solution. The fixed tissues were embedded 
in paraffin and serial sections were cut. Each section was stained with hematoxylin and eosin (H 
& E stain). The sections were examined under light microscope and photomicrographs were 
taken. 
Statistical analysis 
In the present study, all the data was expressed as mean ± S.E.M. Statistical significance 
between more than two groups was tested using one way ANOVA followed by the Tukey test 
using computer based fitting program (Prism graph pad). Statistical significance was set 
accordingly. 
 
 
 
 
Blank Test 
4 ml of homogenate diluted with 2 ml of 
phosphate buffer PH 7, and take absorbance at 
254 nm for 3 min. with 30 sec. interval 
2 ml of homogenate diluted with 1 ml of H2O2 
(8.5 micro lit. in 2.5 ml phosphate buffer 
(50mM/l. pH 7.0) and take the absorbance at 
254 nm for 3 min. with 30 sec. interval. 
(Add H2O2 just before taking O.D) 
6. RESULTS 
The neuroprotective activity was evaluated in Swiss Albino Wistar Rats. Where Group 1 
kept as Normal control, Group 2 received Arsenic trioxide 5 mg/kg p/o, group 3 received 
Arsenic trioxide 5 mg/kg + Diosmin 50 mg/kg p/o and group 4 received Arsenic trioxide 5 
mg/kg + Diosmin 100 mg/kg p/o. at the end of study several parameters like Serum 
Biochemistry, AchE levels, Brain tissue antioxidant levels and Histopathology were evaluated. 
 
Table No. 1 Effect of Diosmin on animal body weights in Arsenic trioxide induced neurotoxicity 
in rats 
Table No. 2 Effect of Diosmin on brain weights in Arsenic trioxide induced neurotoxicity in rats 
Table No. 3 Effect of Diosmin on plasma biochemistry in Arsenic trioxide induced neurotoxicity 
in rats 
Table No. 4 Effect of Diosmin on plasma lipids and lipoproteins in Arsenic trioxide induced 
neurotoxicity in rats 
Table No. 5 Effect of Diosmin on Brain and Serum Acetylcholinesterase levels in Arsenic 
trioxide induced neurotoxicity in rats 
Table No. 6 Effect of Diosmin on Biogenic amines of Corpus striatum in Arsenic trioxide 
induced neurotoxicity in rats 
Table No. 7 Effect of Diosmin on Biogenic amines of Frontal cortex in Arsenic trioxide induced 
neurotoxicity in rats 
Table No. 8 Effect of Diosmin on Biogenic amines of Hippocampus in Arsenic trioxide induced 
neurotoxicity in rats 
Table No. 9 Effect of Diosmin on Brain tissue Antioxidants in Arsenic trioxide induced 
neurotoxicity in rats 
 
 
 
Graphs showing the statistical analysis of various parameters 
 
Graph No.1 Effect of Diosmin on animal body weights in Arsenic trioxide induced neurotoxicity 
in rats 
Graph No. 2 Effect of Diosmin on brain weights in Arsenic trioxide induced neurotoxicity in rats 
Graph No.3 Effect of Diosmin on plasma biochemistry (Total Proteins, Albumin,Glucose, Urea) 
in Arsenic trioxide induced neurotoxicity in rats 
Graph No.4 Effect of Diosmin on plasma biochemistry (Creatinine, Bilirubin) in Arsenic trioxide 
induced neurotoxicity in rats 
Graph No.5Effect of Diosmin on plasma lipids and lipoproteins (Total lipids, Cholesterol, 
Triglycirides, LDL-C) in Arsenic trioxide induced neurotoxicity in rats 
Graph No.6 Effect of Diosmin on plasma lipids and lipoproteins (HDL-C and VLDL-C) in 
Arsenic trioxide induced neurotoxicity in rats 
Graph No.7 Effect of Diosmin on Brain and Serum Acetylcholinesterase levels in Arsenic 
trioxide induced neurotoxicity in rats 
Graph No. 8 Effect of Diosmin on Biogenic amines (Norepinephrine, Epinephrine, Serotonin, 
Homovanilic acid) of Corpus striatum in Arsenic trioxide induced neurotoxicity in rats 
Graph No.9 Effect of Diosmin on Biogenic amines (Dopamine and 3,4- Dihydroxy Phenyl acetic 
acid) of Corpus striatum in Arsenic trioxide induced neurotoxicity in rats 
Graph No.10 Effect of Diosmin on Biogenic amines (Dopamine, 3,4- Dihydroxy Phenyl acetic 
acid, Norepinephrine and epinephrine) of Frontal cortex in Arsenic trioxide induced 
neurotoxicity in rats 
Graph No.11 Effect of Diosmin on Biogenic amines (Serotonin and Homovanilic acid) of Frontal 
cortex in Arsenic trioxide induced neurotoxicity in rats 
Graph No.12 Effect of Diosmin on Biogenic amines (Dopamine, Serotonin, Norepinephrine, 
Epinephrine) of Hippocampus in Arsenic trioxide induced neurotoxicity in rats 
Graph No.13 Effect of Diosmin on Biogenic amines (3,4- Dihydroxy Phenyl acetic acid and 
Homovanilic acid) of Hippocampus in Arsenic trioxide induced neurotoxicity in rats 
Graph No.14 Effect of Diosmin on Brain tissue Antioxidants in Arsenic trioxide induced 
neurotoxicity in rats 
Graph No.15 Effect of Diosmin on Brain tissue Antioxidants in Arsenic trioxide induced 
neurotoxicity in rats 
 
 
 
 
 
 
 
Table No. 1 Effect of Diosmin on animal body weights in Arsenic trioxide induced neurotoxicity in rats 
S.No Treatment Day 1 Day 7 Day 14 Day 28 
1 Normal control 150 ± 2.3 161 ± 3.2 172 ± 2.3 197 ± 3.6 
2 Arscenic trioxide 
(5mg/kg) 
154 ± 1.4 162 ± 2.3 168 ± 2.1* 175 ± 1.9** 
3 Arscenic trioxide 
(5mg/kg) + 
Diosmin (50mg/kg) 
156 ± 2.5 166 ± 1.5 174 ± 3.3# 186 ± 2.8# 
4 Arscenic trioxide 
(5mg/kg) + 
Diosmin 
(100mg/kg) 
160 ± 2.0 169 ± 3.5 177 ± 2.1# 192 ± 3.2## 
 
N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
Daily examination of bodyweights in all the treatment groups during the study showed, reduced weight gain in ATO control 
group when compared to normal control and drug treated groups. 
  
Graph No. 1 Effect of Diosmin on animal body weights in Arsenic trioxide induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
Animals in ATO control group showed a reduced body weight gain when compared to other groups in the scheduled treatment. 
 
Table No. 2 Effect of Diosmin on brain weights in Arsenic trioxide induced neurotoxicity in rats 
 
S.No Treatment Brain weights (gm) 
1 Normal controlTotal PRoteins 1.89 ± 0.91 
2 Arscenic trioxide (5mg/kg) 1.42 ± 0.32** 
3 Arscenic trioxide (5mg/kg) + Diosmin (50mg/kg) 1.68 ± 0.33# 
4 Arscenic trioxide (5mg/kg) + Diosmin (100mg/kg) 1.84 ± 0.96## 
 
 
N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
Measuring the weights of fresh brains just after the isolation at the end of treatment showed that ATO control animals has a 
reduced weight when compared to other groups. 
 
  
Graph No. 2 Effect of Diosmin on brain weights in Arsenic trioxide induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
This graph explains the declined brain weights that were observed at the end of treatment. 
 
 
 
Table No. 3 Effect of Diosmin on plasma biochemistry in Arsenic trioxide induced neurotoxicity in rats 
 
N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
Animals treated with Diosmin 100 mg/kg showed a significant effect on plasma biochemistry in animals given with ATO. 
 
Graph No. 3 Effect of Diosmin on plasma biochemistry (Total Proteins, Albumin,Glucose, Urea) in Arsenic trioxide induced 
neurotoxicity in rats 
S. No Treatment Parameters (mg/dl) 
Total proteins Albumin Glucose Urea Creatinine Bilurubin 
1. Normal control 9.1 ± 0.11 4.2 ± 0.12 116 ± 2.1 22.8 ± 1.4 0.35 ± 0.02 0.64 ± 0.04 
2. Arscenic trioxide 
(5mg/kg) 
7.1 ± 0.54** 3.2 ± 0.15*** 167 ± 4.1*** 37 ± 0.5*** 0.71 ± 
0.02*** 
1.24 ± 
0.05*** 
3. Arscenic trioxide 
(5mg/kg) + Diosmin 
(50mg/kg) 
7.94 ± 0.54*# 3.6 ± 0.40*# 135 ± 2.4**## 30 ± 1.2**# 0.58 ± 0.04**# 0.95 ± 
0.01*** 
4. Arscenic trioxide 
(5mg/kg) + Diosmin 
(100mg/kg) 
8.74 ± 0.12## 3.97 ± 0.51### 120 ± 1.9### 24 ± 0.9### 0.40 ± 0.03### 0.70 ± 0.05### 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
This graph explains the protective nature of Diosmin on plasma proteins, glucose, urea and albumin. 
 
 
 Graph No. 4 Effect of Diosmin on plasma biochemistry (Creatinine, Bilirubin) in Arsenic trioxide induced neurotoxicity in 
rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
This graph explains the protective nature of Diosmin on plasma proteins, glucose, urea and albumin. 
 
  
Table No. 4 Effect of Diosmin on plasma lipids and lipoproteins in Arsenic trioxide induced neurotoxicity in rats 
 
N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
S. 
No 
Treatment Parameters (mg/dl) 
Total lipids Cholesterol  Triglycerides  HDL - C LDL - C VLDL – C 
1. Normal control 242  ± 3.71 85  ± 1.90 52.31  ± 2.11 26.01  ± 1.31 46.01  ± 1.91 11.23 ± 0.57 
2. Arscenic trioxide 
(5mg/kg) 
315  ± 4.01** 108  ± 2.0** 85.00  ± 
3.40*** 
19.01  ± 1.50 70.01  ± 
2.40*** 
36.00 ± 
1.02*** 
3. Arscenic trioxide 
(5mg/kg) + Diosmin 
(50mg/kg) 
294  ± 3.50*# 94  ± 2.10*# 76.01  ± 
3.21*# 
21.02  ± 1.32* 61.20  ± 
2.01*# 
20.05 ± 
1.03**## 
4. Arscenic trioxide 
(5mg/kg) + Diosmin 
(100mg/kg) 
250.1  ± 
3.21### 
89.01  ± 
2.20## 
56.04  ± 
2.91### 
25.21  ± 
1.42## 
49.02  ± 
2.12### 
12.54 ± 
1.01### 
  
Graph No. 5 Effect of Diosmin on plasma lipids and lipoproteins (Total lipids, Cholesterol, Triglycirides, LDL-C) in Arsenic 
trioxide induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, #p<0.01, 
###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by Tukey’s 
multiple comparision test. 
 
  
Graph No. 6 Effect of Diosmin on plasma lipids and lipoproteins (HDL-C and VLDL-C) in Arsenic trioxide induced 
neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
  
Table No. 5 Effect of Diosmin on Brain and Serum Acetylcholinesterase levels in Arsenic trioxide induced neurotoxicity in rats 
S. No Treatment Brain AchE (µ mol substrate 
hydrolysed/ min/mg proteins) 
Serum AchE (µ mol substrate 
hydrolysed/min) 
1. Normal control 10.35 ± 0.91 2.91 ± 0.15 
2. Arscenic trioxide 
(5mg/kg) 
5.32 ± 0.35*** 2.01 ± 0.12* 
3. Arscenic trioxide 
(5mg/kg) + Diosmin 
(50mg/kg) 
7.52 ± 0.41*# 2.40 ± 0.15## 
4. Arscenic trioxide 
(5mg/kg) + Diosmin 
(100mg/kg) 
9.41 ± 0.202### 2.72 ± 0.01### 
 
N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
 
  
Graph No.7 Effect of Diosmin on Brain and Serum Acetylcholinesterase levels in Arsenic trioxide induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
 
  
Table No. 6 Effect of Diosmin on Biogenic amines of Corpus striatum in Arsenic trioxide induced neurotoxicity in rats 
S. No Treatment Biogenic amines (ng/gm tissue weight) 
Dopamine  Norepinephrine Epinephrine  serotonin 3, 4 -  dihydroxy 
phenyl acetic acid  
Homovanilic 
acid 
1. Normal control 4395 ± 148 692 ± 59.20 320 ± 21.50 941 ± 81 3120 ± 192 509 ± 35.81 
2. Arscenic trioxide 
(5mg/kg) 
3042 ± 
152*** 
321 ± 63.31*** 149 ± 
10.90*** 
521 ± 
75*** 
2257 ± 160*** 328 ± 
10.02*** 
3. Arscenic trioxide 
(5mg/kg) + Diosmin 
(50mg/kg) 
3951 ± 160*# 452 ± 45.01## 265 ± 11.05## 745 ± 
64## 
2850 ± 152*### 420 ± 
11.05*## 
4. Arscenic trioxide 
(5mg/kg) + Diosmin 
(100mg/kg) 
4320 ± 150### 602 ± 50.01## 298 ± 10.11### 894 ± 
32## 
3010 ± 142### 495 ± 12.11### 
 
N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
 Graph No. 8 Effect of Diosmin on Biogenic amines (Norepinephrine, Epinephrine, Serotonin, Homovanilic acid) of Corpus 
striatum in Arsenic trioxide induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
 
 
 
Graph No. 9 Effect of Diosmin on Biogenic amines (Dopamine and 3,4- Dihydroxy Phenyl acetic acid) of Corpus striatum in 
Arsenic trioxide induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
  
Table No. 7 Effect of Diosmin on Biogenic amines of Frontal cortex in Arsenic trioxide induced neurotoxicity in rats 
S. No Treatment Biogenic amines (ng/gm tissue weight) 
Dopamine  Norepinephrine Epinephrine  serotonin 3, 4 dihydroxy 
phenyl acetic 
acid  
Homovanilic 
acid 
1. Normal control 1050 ± 60.12 240 ± 20.01 312 ± 35.12 769 ± 25.42 351 ± 29.12 95 ± 4.24 
2. Arscenic trioxide 
(5mg/kg) 
450 ± 
51.02*** 
176 ± 5.42*** 145 ± 
37.42*** 
541 ± 
26.42*** 
215 ± 30.10*** 56 ± 3.17** 
3. Arscenic trioxide 
(5mg/kg) + Diosmin 
(50mg/kg) 
812 ± 
45.12*### 
189 ± 4.40* 204 ± 19.11## 623 ± 
25.91## 
270 ± 30.13## 70 ± 4.02*## 
4. Arscenic trioxide 
(5mg/kg) + Diosmin 
(100mg/kg) 
984 ± 31.05### 228 ± 3.40### 293 ± 10.54### 729 ± 
25.54### 
298 ± 27.42*## 89 ± 5.16### 
 
N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
 
Graph No. 10 Effect of Diosmin on Biogenic amines (Dopamine, 3,4- Dihydroxy Phenyl acetic acid, Norepinephrine and 
epinephrine) of Frontal cortex in Arsenic trioxide induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
  
Graph No. 11 Effect of Diosmin on Biogenic amines (Serotonin and Homovanilic acid) of Frontal cortex in Arsenic trioxide 
induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
 
Table No. 8 Effect of Diosmin on Biogenic amines of Hippocampus in Arsenic trioxide induced neurotoxicity in rats 
S. No Treatment Biogenic amines (ng/gm tissue weight) 
Dopamine  Norepinephrine Epinephrine  serotonin 3, 4 dihydroxy 
phenyl acetic 
acid  
Homovanilic 
acid 
1. Normal control 361 ± 10.02 165 ± 14.81 281 ± 9.36 319 ± 15.74 41.59 ± 7.14 37.47 ± 4.89 
2. Arscenic trioxide 
(5mg/kg) 
235 ± 
15.02*** 
101 ± 9.48*** 192 ± 4.42*** 142 ± 
5.20*** 
25.42 ± 
4.56*** 
19.42 ± 
3.72*** 
3. Arscenic trioxide 
(5mg/kg) + Diosmin 
(50mg/kg) 
285 ± 12.14## 121 ± 7.01*# 215 ± 5.03# 218 ± 
10.03## 
29.52 ± 5.03# 24.91 ± 4.52# 
4. Arscenic trioxide 
(5mg/kg) + Diosmin 
(100mg/kg) 
308 ± 14.12### 146 ± 8.23## 260 ± 7.16### 298 ± 
12.42### 
36.42 ± 4.49## 32.98 ± 
3.44### 
 
N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
 
Graph No. 12 Effect of Diosmin on Biogenic amines (Dopamine, Serotonin, Norepinephrine, Epinephrine) of Hippocampus in 
Arsenic trioxide induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
 
 
 
Graph No. 13 Effect of Diosmin on Biogenic amines (3,4- Dihydroxy Phenyl acetic acid and Homovanilic acid) of 
Hippocampus in Arsenic trioxide induced neurotoxicity in rats 
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N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
Table No. 9 Effect of Diosmin on Brain tissue Antioxidants in Arsenic trioxide induced neurotoxicity in rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; #p<0.05, 
#p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed by 
Tukey’s multiple comparision test. 
 
 
S.No Treatment LPO 
(nM /mg 
protein) 
SOD 
(Units/mg 
protein) 
GSH 
(µg of GSH/mg 
protein) 
CAT 
(µ moles of H2O2 
consumed/min/mg) 
1 Normal control 4.73 ± 0.34 18.47 ± 1.00 142.5 ± 3.22 1.49  ± 0.04 
2 Arscenic trioxide 
(5mg/kg) 
10.34 ± 0.55### 9.60 ± 0.82### 71.83 ± 4.67### 0.53  ± 0.02### 
3 Arscenic trioxide 
(5mg/kg) + Diosmin 
(50mg/kg) 
7.69 ± 0.74** 13.46 ± 1.18* 110.2 ± 10.80** 0.80  ± 0.01** 
4 Arscenic trioxide 
(5mg/kg) + Diosmin 
(100mg/kg) 
5.52 ± 0.28*** 15.97 ± 0.61*** 131.30  ± 3.16*** 1.09  ± 0.06*** 
Graph No. 14 Effect of Diosmin on Brain tissue Antioxidants in Arsenic trioxide induced neurotoxicity in rats 
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 N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; 
#p<0.05, #p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed 
by Tukey’s multiple comparision test. 
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Graph No. 15 Effect of Diosmin on Brain tissue Antioxidants in Arsenic trioxide induced neurotoxicity in rats 
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 N = 6; values were expressed as Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 when compared to normal control; 
#p<0.05, #p<0.01, ###p<0.001 when compared to arsenic trioxide treatment group. Data were analysed by one way ANOVA followed 
by Tukey’s multiple comparision test. 
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7. HISTOPATHOLOGY 
Photo micrograph of Brain showing normal cytoarchitecture of normal control animals: 
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Photo micrograph of Brain showing degenerated neural cells of ATO (5 mg/kg) control 
animals: 
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Photo micrograph of Brain showing normal cytoarchitecture and recovering cells of 
animals treated with ATO (5 mg/kg) + Diosmin (50 mg/kg) 
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Photo micrograph of Brain showing normal cytoarchitecture of animals treated with ATO 
(5 mg/kg) + Diosmin (100 mg/kg) 
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8. DISCUSSION 
Neuroprotective effect of Diosmin was evaluated using Arsenic trioxide as inducing 
agent in wistar rats. Statistical analysis of change in body weights, weights of brain, serum 
biochemical parameters, biogenic amines, serum and brain AchE levels and brain tissue 
antioxidant profile evaluation was done using instant prism graph pad (Ver 4.0).  
Results revealed that treatment with ATO showed a significant decrease in plasma total 
protein (TP) and albumin (A). On the other hand, treatment with ATO caused a significant 
increase in the concentrations of plasma glucose, urea, creatinine and bilirubin as compared to 
control. The decline in plasma total protein due to treatment with ATO was mainly due to the 
decrease in albumin fraction.132, 114, 115 
The inhibitory effect of ATO on protein profile showed that arsenic inhibited the ability 
of glucocorticoid and its receptor to turn on genes normally. The glucocorticoid hormonal system 
plays an important role in protein metabolism. The reduction in plasma protein in animals 
exposed to environmental pollutants could be attributed to changes in protein and free amino 
acid metabolism and their synthesis in the liver.  
In addition, the protein depression in the blood was also reported to be mainly due to 
excessive loss through nephrosis. Also, may be due to reduced protein synthesis or increased 
proteolytic activity or degradation. The observed decrease in plasma proteins could be also 
attributed in part to the damaging effect of ATO on liver cells. 
The increased glucose production and decreased glucose utilization would lead to 
hyperglycemia. Oxidative stress (OS) has been suggested as a major pathogenic link to both 
insulin resistance and beta cell dysfunction. 114, 115  
Oxidative stress causes structural damages to the pancreatic islets with the formation of 
amyloid proteins, which not only prevents the release of insulin into the circulation, but also 
destroys the insulin-secreting beta cells insidiously after prolonged exposure to arsenic. 
The elevation in plasma urea level in ATO treated rats is considered as a significant 
marker of renal dysfunction. The blood urea becomes raised when the kidney tubules are 
prevented from removing the urea and other waste products from the blood. Elevated blood urea 
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is correlated with an increased protein catabolism in mammalian body or from more efficient 
conversion of ammonia to urea as a result of increased synthesis of enzyme involved in urea 
production.  
Also, the high levels of blood urea results from either increased breakdown of tissue, 
dietary or impaired excretion. Moreover, the increase in urea concentrations in plasma of animals 
treated with ATO may be due to its effect on liver function, as urea is the end-product of protein 
catabolism and this is confirmed by the decrease in plasma. 
The present study indicated that treatment with ATO caused significant increase in 
plasma creatinine and urea. Low clearance values for creatinine and urea indicate diminished 
ability of the kidneys to filter these waste products from the blood and excrete them in the urine. 
Thomas et al. found that the induction rate in serum bilirubin was associated with free 
radical production. The lipophilic reactive oxygen species act directly on bilirubin, leading to its 
oxidation to biliverdin. Radicals derived directly from arsenic or during its metabolism, and they 
play an important role in the nephrotoxicity by increasing lipid peroxidation.132  
The increase in plasma bilirubin (hyper-bilirubenimia) may be resulted from decreased 
liver uptake, conjugation or increased bilirubin production from hemolysis. Also, the elevation in 
plasma bilirubin concentration could be due to the onset of periportal necrosis. 114, 115, 133  
The present data indicated that plasma TL, cholesterol, TG and LDL-c were significantly 
increased by ATO treatment, while HDL levels were decreased. 
The present results showed that treatment with Diosmin alone caused a significant 
decrease in glucose, urea, creatinine, TL, cholesterol, TG and LDL-c, but did not cause changes 
in TP, A, G and bilirubin. Diosmin treatment significantly attenuated the ATO mediated increase 
in plasma glucose, urea, and creatinine, and decrease in total protein and albumin.  
This effect may be related to the antioxidant properties of Diosmin, since it has been 
found that ROS may be involved in the impairment of glomerular filtration rate. 
The decrease in glucose level of rats treated with Diosmin reported that daily intake 
reduce the blood sugar level. 
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Acetyl cholinesterase (AChE) is one of many important enzymes needed for the proper 
functioning of the nervous systems of humans, other vertebrates and insects.133 
The data obtained from this study clearly show that arsenic trioxide significantly 
decreased the activity of serum acetyl cholinesterase. The results agree with previous studies that 
demonstrated a decreased activity of acetyl cholinesterase in neuroblastoma cells of mice, in rat 
whole brain and in two models of fish. 
The inhibition of acetyl cholinesterase by arsenic trioxide is a puzzling phenomenon 
because AChE does not contain the structural features usually associated with the inhibition of 
enzymes by arsenic.  
Trivalent arsenic compounds are potent inhibitors of a number of enzymes but the 
mechanism of this inhibition is the reaction of the arsenical with free sulfhydryl groups, notably 
those of reduced lipoic acid, to form cyclic thio-arsenite diesters. The enzyme has been found to 
contain cysteine only in the form of disulfide bridges and not as free thiol. 
Biogenic amines are important regulators of various physiological and pharmacological 
functions in the biological system. Fluctuations in the levels of biogenic amines may affect the 
signaling process and behavioral functions. Alterations in the levels of brain catecholamines, 5-
HT and their metabolites have been observed in chemical-induced neurodegeneration and also in 
neurodegenerative diseases.140 
Although a number of studies have been carried out to investigate the role of biogenic 
amines including DA, NE, EPN and 5-HT and their metabolites in arsenic-induced neurotoxicity, 
consistent changes have not been observed. 
In our study upon given with ATO showed a significant reduction in the biogenic amines 
( dopamine, NE, Epinephrine, 5 HT, Homovanilic acid and 3, 4 – dihydroxy phenyl acetic acid) 
indicating the reduced neuronal function of different regions of brain ( Corpus striatum, frontal 
cortex, hippocampus). Treatment with Diosmin in rats revealed a successful recovery in the 
production of biogenic amines replacing the active neuronal functions. 
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In the present study, various antioxidant parameters were assessed in the brain at the end 
of the study. 
The thiobarbituric acid reacting substance assay is used as an indicator of lipid 
peroxidation and levels of free radicals. The assay is based on the reactions of thiobarbituric acid 
with malondialdehyde produced during lipid peroxidation. 
The results showed that the effect of ATO was significant in increasing in 
malondialdehyde when compared with the normal group. Treatment with Diosmin showed 
significant decrease in malondialdehyde when compared to ATO treated group. 
Superoxide dismutase is an important endogenous antioxidant and prevents production of 
free radicals. The decrease in superoxide dismutase is observed in ATO treated group compared 
normal group. The results from treatment with Diosmin showed that a significant rise in SOD 
levels revealed the protective effect of the Diosmin. 
Reduced Glutathione (GSH) is one of the primary endogeneous antioxidant defense 
systems in brain, which removes hydrogen peroxides and lipid peroxidase. Decline in GSH 
levels could either increase or reflect oxidative state. 
The decrease in GSH is observed in ATO treated group compared to normal group. 
Treatment with Diosmin brought the GSH to the normal levels when compared to ATO treated 
animals. 
An increase in production of catalase leads to the accumulation of hydrogen peroxidase, 
which is converted to hydroxyl radicals that produced deleterious effect on brain. Catalase 
decomposes hydrogen peroxidase and converts it to water and diatomic oxygen, whereas 
superoxide dismutase generates H2O2 from free radicals. 
The decrease in H2O2 consumed is observed in ATO treated group compared to normal 
group. The results from the Diosmin treatment showed that catalase levels were significantly 
recovered when compared to ATO treated group, and no significant difference was observed 
when compared to normal control. 
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Histopathological studies of the normal control brain showed normal cytoarchitecture in 
brain. In arsenic trioxide treated group of animals showed the congestion of degenerative 
changes due to decrease in the number of neural cells in brain.  
Animals treated with Diosmin at a dose of 50 mg/kg showed regenerative changes in 
brain. Interestingly high dose of Diosmin 100 mg/kg treated rats showed almost normal 
cytoarchitecture of brain. 
Despite its protective actions on the central nervous system, there have been very limited 
studies of the effects of Diosmin on the brain and behaviour. Therefore, the present study 
provided new insights on the neurotoxicity of arsenic. 
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9. CONCLUSION 
In summary, the results of the present study suggest that arsenic neurotoxicity in rats 
initiated peroxidative reactions in membrane lipids of the brain.  
The present study demonstrates the inhibitory effect of Diosmin pretreatment on the brain 
oxidative stress in an in vivo model. Histopathological evaluation revealed the neuroprotective 
effect of Diosmin mainly at a dose of Diosmin 100 mg/kg. 
Treatment with Diosmin revealed a significant amelioration in arsenic induced 
neurotoxicity showing its protective effect by improving the Biogenic amines in various regions 
of brain and the AchE levels in serum and brain. 
These findings derive the significance of Diosmin in ameliorating the oxidative stress and 
neuroinflammation which are important contributors in the pathogenesis of several 
neurodegenerative disorders.  
Furthermore, it is implicated that arsenic is a de-myelinating agent. And may alter 
neuronal functions followed by CNS dysfunctions. 
Much remains to be learned about this ancient neurotoxicant. It is planned in future to 
study the effects of arsenic in brain with respect to myelin structure and functions, DNA and 
RNA levels and to seek a correlation with oxidant stress, and to estimate the levels of antioxidant 
defence system enzymes. 
 
 
 
 
 
 
 
 
 
88 
 
10. REFERENCES 
1. Winship, K.A., 1984. Toxicity of inorganic arsenic salts. Adverse Drug Reactions and 
Acute Poisoning Reviews3, 129-160. 
2. Vahter, M., Concha, G., 2001. Role of metabolism in arsenic toxicity. Pharmacology and 
Toxicology 89, 1-5. 
3. Styblo, M., Del Razo, L.M., Vega, L., Germolec, D.R., LeCluyse, E.L., Hamilton, G.A., 
Reed, W., Wang, C., Cullen, W.R., and Thomas, D.J., 2000. Comparative toxicity of 
trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. 
Archives of Toxicology 74, 289-299. 
4. Lagerkvist, B.J., Zetterlund, B., 1994. Assessment of exposure to arsenic among smelter 
workers: a five-year follow-up. American Journal of Industrial Medicine 25, 477-488. 
5. Le Quesne, P.M. and McLeod, J.G., 1977. Peripheral neuropathy following a single 
exposure to arsenic. Clinical course in four patients with electrophysiological and 
histological studies. Journal of the Neurological Sciences 32, 437-451. 
6. Rahman, M.M., Chowdhury, U.K., Mukherjee, S.C., Mondal, B.K., Paul, K., Lodh, D., 
Biswas, B.K., Chanda, C.R., Basu, G.K., Saha, K.C., Roy, S., Das, R., Palit, S.K., 
Quamruzzaman, Q., and Chakraborti, D., 2001. Chronic arsenic toxicity in Bangladesh 
and West Bengal, India--a review and commentary. Journal of Toxicology - Clinical 
Toxicology 39, 683-700. 
7. Hughes, M.F., 2002. Arsenic toxicity and potential mechanisms of action. Toxicology 
Letters 133, 1-16. 
8. Hei, T.K., Filipic, M., 2004. Role of oxidative damage in the genotoxicity of arsenic. 
Free Radical Biology and Medicine 37, 574-581. 
9. Cushnie, TPT, Lamb, AJ. Antimicrobial activity of flavonoids. International Journal of 
Antimicrobial Agents. 2005; 26: 343-356. 
10. Murray, MT. Quercetin: Nature’s antihistamine. Better Nutrition. 1998;24:12-4. 
11. Williams, RJ, Spencer, JPE, and Rice-Evans, C. Serial review: Flavonoids and 
isoflavonones (Phytoestrogens): Absorption, Metabolism and Bioactivity. Free Radical 
Biology and Medicine. 2004;36: 838-849  
12. Cook, NC, Samman, S. Flavonoids: Chemistry, metabolism, cardioprotective effects and 
dietary sources. Nutritional Biochemistry. 1996; 7: 66-76.  
89 
 
13. Narayana, KR, Reddy, SR, Chaluvadi, MR, Krishna, DR. Bioflavonoids classification, 
pharmacological, biochemical effects and therapeutic very goodial. Indian Journal of 
Pharmacology. 2001;33: 2-16.  
14. Tamamoto LC, Schmidt SJ, Lee SY. Sensory profile of a model energy drink with 
varying levels of functional ingredients-caffeine, ginseng, and taurine. J Food Sci. 2010; 
75:S271-8. 
15. Srinivasan S, Pari L. Ameliorative effect of diosmin, a citrus flavonoid against 
streptozotocin-nicotinamide generated oxidative stress induced diabetic rats. Chem Biol 
Interact. 2012;195:43-51. 
16. Steingass A. A Comprehensive Persian English Dictionary, Kegan Paul, Trench, Trubner 
& co., LTD.,London 1947. 
17. Dich J, Zahm SH, Hanberg A, Adami HO. Pesticides and cancer. Cancer Causes Control 
1997; 8: 420-43. 
18. Yip SF, Yeung YM, Tsui EY. Severe neurotoxicity following arsenic therapy for acute 
promyelocyticleukemia: potentiation by thiamine deficiency. Blood 2002; 99: 3481-82. 
19. Espinoza EO, Mann MJ, Bleasdell B. Arsenic and mercury in traditional Chinese herbal 
balls. N Engl JMed 1995; 333: 803-804. 
20. Ong ES, Yong YL, Woo SO. Determination of arsenic in traditional Chinese medicine by 
microwavedigestion with flow injection-inductively coupled plasma mass spectrometry 
(FI-ICP-MS). J AOAC Int1999; 82: 963-67. 
21. Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, Phillips RS. Heavy 
metal contentof ayurvedic herbal medicine products. JAMA 2004; 292: 2868-73. 
22. Lynch E, Braithwaite R. A review of the clinical and toxicological aspects of 'traditional' 
(herbal)medicines adulterated with heavy metals. Expert Opin Drug Saf 2005; 4: 769-78. 
23. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, Waxman S. Combined effect of 
all-transretinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro 
and in vivo. Blood2001; 97: 264-69. 
24. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, 
Tang W, WuF, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z. Studies on the clinical 
efficacy and pharmacokinetics oflow-dose arsenic trioxide in the treatment of relapsed 
90 
 
acute promyelocytic leukemia: a comparison withconventional dosage. Leukemia 2001; 
15: 735-41. 
25. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S, Mechanisms of action of 
arsenic trioxide.Cancer Res 2002; 62: 3893-3903. 
26. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best 
Pract Res ClinHaematol 2007; 20: 57-65. 
27. Brouwer OF, Onkenhout W, Edelbroek PM, de Kom JF, de Wolff FA, Peters AC, 
Increasedneurotoxicity of arsenic in methylenetetrahydrofolate reductase deficiency. Clin 
Neurol Neurosur1992;94: 307-310.Review21 
28. Heaven R, Duncan M, Vukelja SJ. Arsenic intoxication presenting with macrocytosis and 
peripheralneuropathy, without anemia. Acta Haematol 1994; 92: 142-43. 
29. De Wolff FA, Edelbroek PM. Neurotoxicity of arsenic and its compounds. In Handbook 
of Clinical Neurology ed. by Vinken & Bruyn's, Elsevier Science B.V. 1994; 283-291. 
30. Wilkinson SP, McHugh P, Horsley S, Tubbs H, Lewis M, Thould A, Winterton M, 
Parsons V, WilliamsR. Arsine toxicity aboard the Asiafreighter. Br Med J 1975; 3: 559-
563. 
31. Pullen-James S, Woods SE. Occupational arsine gas exposure. J Natl Med Assoc 2006; 
98: 1998-2001. 
32. Greenberg SA. Acute demyelinating polyneuropathy with arsenic ingestion. Muscle 
Nerve 1996; 19:1611-13. 
33. Le Quesne PM, McLeod JG. Peripheral neuropathy following a single exposure to 
arsenic. Clincalcourse in four patients with electrophysiological and histological studies. 
J Neurol Sci 1977; 32: 437-51. 
34. Centeno JA, Tseng CH, van der Voet GB, Finkelman RB. Global impacts of geogenic 
arsenic: amedical geology research case. Ambio. 2007; 36: 78-81. 
35. Kelynack TNV. Lond MRCD. Arsenical poisoning from beer drinking. The Lancet 
1900;1600-1603. 
36. Buchanan RJM, Lond MRCD. Cases of arsenical peripheral neuritis. The Lancet 1901; 
170-72. 
91 
 
37. Mayans MV, Robertson SE, Duclos P. Adverse events monitoring as a routine 
component of vaccineclinical trials: evidence from the WHO Vaccine Trial Registry. Bull 
World Health Organ 2000; 78:1167. 
38. Mukherjee A, Sengupta MK, Hossain MA, Ahamed S, Das B, Nayak B, Lodh D, 
Rahman MM,Chakraborti D. Arsenic contamination in groundwater: a global perspective 
with emphasis on the Asianscenario. J Health Popul Nutr 2006; 24: 142-63. 
39. Mees RA. Een verschijnsel bij polyneuritis arsenicosa. Ned Tijdsch Geneeskd 1919; 1: 
391-96. 
40. Chen C.J, Wang SL, Chiou JM, Tseng CH, Chiou HY, Hsueh YM, Chen SY, Wu MM, 
Lai MS. Arsenic and diabetes and hypertension in human populations: A review. Toxicol 
Appl Pharmacol 2007. 
41. Chowdhury UK, Biswas BK, Chowdhury TR, Samanta G, Mandal BK, Basu GC, Chanda 
CR, Lodh D, Saha KC, Mukherjee SK, Roy S, Kabir S, Quamruzzaman Q, Chakraborti 
D. Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ 
Health Perspect 2000; 108: 393-97. 
42. Centeno JA, Mullick FG, Martinez L, Page NP, Gibb H, Longfellow D, Thompson C, 
Ladich ER. Pathology related to chronic arsenic exposure. Environ. Health Perspect 
2002; 110: 883-86. 
43. Hafeman DM, Ahsan H, Louis ED, Siddique AB, Slavkovich V, Cheng Z, van Geen A, 
Graziano JH. Association between arsenic exposure and a measure of subclinical sensory 
neuropathy in Bangladesh. J Occup Environ Med 2005; 47: 778-84. 
44. Enterline PE, Henderson VL, Marsh GM. Exposure to arsenic and respiratory cancer. A 
reanalysis. Am J Epidemiol 1987; 125: 929-38. 
45. Hertz-Picciotto I, Smith AH. Observations on the dose-response curve for arsenic 
exposure and lung cancer. Scand. J Work Environ Health 1993; 19: 217-26. 
46. Mandal BK, Ogra Y. Anzai K, Suzuki KT. Speciation of arsenic in biological samples. 
Toxicol Appl Pharmacol 2004; 198; 307-318. 
47. Aposhian HV. Enzymatic methylation of arsenic species and other new approaches to 
arsenic toxicity. Annu Rev Pharmacol Toxicol 1997; 37: 397-419. 
48. Vahter M, Concha G. Role of metabolism in arsenic toxicity. Pharmacol Toxicol 2001; 
89: 1-5. 
92 
 
49. Hughes MF. Arsenic toxicity and potential mechanisms of action. Toxicol Lett 2002; 
133: 1-16.  
50. Buchet JP, Lauwerys R. Study of inorganic arsenic methylation by rat liver in vitro: 
relevance for the interpretation of observations in man. Arch Toxicol 1985; 57: 125-29. 
51. Buchet JP, Lauwerys R. Role of thiols in the in-vitro methylation of inorganic arsenic by 
rat liver cytosol. Biochem Pharmacol 1988; 37: 3149-53. 
52. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, 
Wang C, Cullen WR, Thomas DJ. Comparative toxicity of trivalent and pentavalent 
inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 2000; 74: 289-
99. 
53. Shirachi DY, Lakso JU, Rose LJ. Methylation of sodium arsenate by rat liver in vitro. 
Proc West Pharmacol Soc 1981; 24: 159-60. 
54. Kitagawa F, Shiomi K, Otsuka K. Analysis of arsenic compounds by capillary 
electrophoresis using indirect UV and mass spectrometric detections. Electrophoresis 
2006; 27: 2233-39. 
55. Yamamoto S, Konishi Y, Matsuda T, Murai T, Shibata MA, Matsui-Yuasa I, Otani S, 
Kuroda K, Endo G, Fukushima S. Cancer induction by an organic arsenic compound, 
dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five 
carcinogens. Cancer Res 1995; 55: 1271-76. 
56. Wanibuchi H, Yamamoto S, Chen H, Yoshida K, Endo G, Hori T, Fukushima S. 
Promoting effects of dimethylarsinic acid on N-butyl-N-(4-hydroxybutyl)nitrosamine-
induced urinary bladder carcinogenesis in rats. Carcinogenesis 1996; 17: 2435-39. 
57. Csanaky I, Gregus Z. Species variations in the biliary and urinary excretion of arsenate, 
arsenite and their metabolites. Comp Biochem Physiol C Toxicol Pharmacol 2002; 131: 
355-65. 
58. Aposhian HV, Zakharyan RA, Avram MD, Sampayo-Reyes A, Wollenberg ML. A 
review of the enzymology of arsenic metabolism and a new potential role of hydrogen 
peroxide in the detoxication of the trivalent arsenic species. Toxicol Appl Pharmacol 
2004; 198: 327-35. 
59. Andrew AS, Burgess JL, Meza MM, Demidenko E, Waugh MG, Hamilton JW, Karagas 
MR. Arsenic exposure is associated with decreased DNA repair in vitro and in 
93 
 
individuals exposed to drinking water arsenic. Environ Health Perspect 2006; 114: 1193-
98. 
60. Akay C, Thomas III C, Gazitt Y. Arsenic trioxide and paclitaxel induce apoptosis by 
different mechanisms. Cell Cycle 2004; 3: 324-34. 
61. Saha JC, Dikshit AK, Bandyopadhyay M, Saha KC. A Review of Arsenic Poisoning and 
its Effects on Human Health. Critical Reviews in Environmental Science and 
Technology, 1999; 29: 281-313. 
62. Samikkannu T, Chen CH, Yih LH, Wang AS, Lin SY, Chen TC, Jan KY. Reactive 
oxygen species are involved in arsenic trioxide inhibition of pyruvate dehydrogenase 
activity. Chem Res Toxicol 2003; 16: 409-414. 
63. Szinicz L, Forth W. Effect of As2O3 on gluconeogenesis. Arch Toxicol 1988; 61: 444-
49. 
64. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2',7'-dichlorofluorescin as 
an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 
1992; 5: 227-31. 
65. Laurence Brunton, John Lazo, Keith Parker, John S. Lazo. Goodman & Gilman's The 
Pharmacological Basis of Therapeutics, Eleventh Edition. Hevay metal toxicity.  
66. Hall AH. Chronic arsenic poisoning. Toxicol Lett 2002; 128: 69-72. 
67. Tseng HP, Wang YH, Wu MM, The HW, Chiou HY, Chen CJ. Association between 
chronic exposure to arsenic and slow nerve conduction velocity among adolescents in 
Taiwan. J Health Popul Nutr 2006; 24: 182-89. 
68. Rahman MM, Chowdhury UK, Mukherjee SC, Mondal BK, Paul K, Lodh D, Biswas BK, 
Chanda CR, Basu GK, Saha KC, Roy S, Das R, Palit SK, Quamruzzaman Q, Chakraborti 
D. Chronic arsenic toxicity in Bangladesh and West Bengal, India--a review and 
commentary. J Toxicol Clin Toxicol 2001; 39: 683-700. 
69. Monnet-Tschudi F, Zurich MG, Boschat C, Corbaz A, Honegger P. Involvement of 
environmental mercury and lead in the etiology of neurodegenerative diseases. Rev 
Environ Health 2006; 21: 105-117. 
70. van der Voet GB, Marani E, Tio S, De Wolff and FA, Aluminum neurotoxicity. In Prog 
Histochem Cytochem ed. by W. Graumann and J. Gustav Fischer Verlag, Stuttgart; New 
York 1991; 235-42. 
94 
 
71. Shin RW, Lee VM, Trojanowski JQ. Neurofibrillary pathology and aluminum in 
Alzheimer's disease. Histol Histopathol 1995; 10: 969-78. 
72. Kaur A, Joshi K, Minz RW, Gill KD, Neurofilament phosphorylation and disruption: a 
possible mechanism of chronic aluminium toxicity in Wistar rats. Toxicology 2006; 219: 
1-10. 
73. Kamel F, Umbach DM, Munsat TL, Shefner JM, Hu H, Sandler DP. Lead exposure and 
amyotrophic lateral sclerosis. Epidemiology 2002; 13: 311-19. 
74. Kamel F, Umbach DM, Hu H, Munsat TL, Shefner JM, Taylor JA, Sandler DP. Lead 
exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener Dis 2005; 2: 
195-201. 
75. Al Chalabi A, Leigh PN. Recent advances in amyotrophic lateral sclerosis. Curr Opin 
Neurol 2000; 13: 397-405. 
76. Bowler RM, Roels HA, Nakagawa S, Drezgic M, Diamond E, Park R, Koller W, Bowler 
RP, Mergler D, Bouchard M, Smith D, Gwiazda R, Doty RL. Dose-effect relationships 
between manganese exposure and neurological, neuropsychological and pulmonary 
function in confined space bridge welders. Occup Environ Med 2007; 64: 167-77. 
77. Yokel RA. Blood-brain barrier flux of aluminum, manganese, iron and other metals 
suspected to contribute to metal-induced neurodegeneration. J Alzheimers Dis 2006; 10: 
223-53. 
78. Al Chalabi A, Miller CC. Neurofilaments and neurological disease. Bioessays 2003; 25: 
346-55.  
79. Lacoste-Royal G, Mathieu M, Nalbantoglu J, Julien JP, Gauthier S, Gauvreau and D. 
Lack of association between two restriction fragment length polymorphisms in the genes 
for the light and heavy neurofilament proteins and Alzheimer's disease. Can J Neurol Sci 
1990; 17: 302-305. 
80. Vahidnia A, Romijn F, Tiller M, v. d. Voet GB, De Wolff FA, Arsenic-Induced Toxicity: 
Effect on Protein Composition in Sciatic Nerve. Hum Exp Toxicol 2006; 25: 667-74. 
81. Carpenter DA, Ip W. Neurofilament triplet protein interactions: evidence for the 
preferred formation of NF-L-containing dimers and a putative function for the end 
domains. J Cell Sci 1996; 109: 2493-98. 
95 
 
82. Vahidnia A, van der Straaten RJHM, Romijn F. van Pelt J, van der Voet GB, De Wolff 
and FA. Arsenic metabolites affect expression of the neurofilament and tau genes: An in-
vitro study into the mechanism of arsenic neurotoxicity. Toxicol In Vitro . 2007. In Press. 
doi:10.1016/j.tiv.2007.04.007 
83. Florea AM, Splettstoesser F, Büsselberg D. Arsenic trioxide (As2O3) induced calcium 
signals and cytotoxicity in two human cell lines: SY-5Y neuroblastoma and 293 
embryonic kidney (HEK). Toxicol Appl Pharmacol 2007; 220: 292-301. 
84. Ray SK, Fidan M, Nowak MW, Wilford GG, Hogan EL, Banik NL. Oxidative stress and 
Ca2+ influx upregulate calpain and induce apoptosis in PC12 cells. Brain Res 2000; 852: 
326-34. 
85. Kunz S, Niederberger E, Ehnert C, Coste O, Pfenninger A, Kruip J, Wendrich TM, 
Schmidtko A, Tegeder I, Geisslinger G. The calpain inhibitor MDL 28170 prevents 
inflammation-induced neurofilament light chain breakdown in the spinal cord and 
reduces thermal hyperalgesia. Pain 2004; 409-418. 
86. Lopez-Picon FR, Kukko-Lukjanov TK, Holopainen IE. The calpain inhibitor MDL-
28170 and the AMPA/KA receptor antagonist CNQX inhibit neurofilament degradation 
and enhance neuronal survival in kainic acid-treated hippocampal slice cultures. Eur J 
Neurosci 2006; 23: 2686-94. 
87. Giasson BI, Sampathu DM, Wilson CA, Vogelsberg-Ragaglia V, Mushynski WE, Lee 
and VM, The environmental toxin arsenite induces tau hyperphosphorylation. 
Biochemistry 2002; 41: 15376-87. 
88. Vantroyen B, Heilier JF, Meulemans A, Michels A, Buchet JP, Vanderschueren S, 
Haufroid V, Sabbe M. Survival after a lethal dose of arsenic trioxide. J Toxicol Clin 
Toxicol 2004; 42: 889-95. 
89. Perriol MP, Devos D, Hurtevent JF, Tiffreau V, Saulnier F, Destee A, Defebvre L. A case 
of neuropathy mimicking Guillain-Barre syndrome after arsenic intoxication. Rev Neurol 
2006; 162: 374-77. 
90. Stenehjem AE, Vahter M, Nermell B, Aasen J, Lierhagen S, Morland J, Jacobsen D. 
Slow recovery from severe inorganic arsenic poisoning despite treatment with DMSA 
(2.3-dimercaptosuccinic acid). Clin Toxicol 2007; 45: 424-28. 
96 
 
91. Hilmy AM, el Domiaty NA, Kamal MA, Mohamed MA, Abou Samra WE. Effect of 
some arsenic antagonists on the toxicity, distribution and excretion of arsenite and 
arsenate in rats. Comp Biochem Physiol C 1991; 99: 357-62. 
92. Hall AH. Chronic arsenic poisoning. Toxicol Lett 2002; 128: 69-72. 
93. Enterline PE, Henderson VL, Marsh GM. Exposure to arsenic and respiratory cancer. A 
reanalysis. Am J Epidemiol 1987; 125: 929-38. 
94. Morin JP, Viotte G, Vandewalle A.  Gentamicin-induced nephrotoxicity: A cell biology 
approach. Kidney Int. 1980;18:583-90.  
95. Choudhury D, Ahmed Z.  Drug induced nephrotoxicity.  J  Lab Clin Med. 2006; 
147(4):160-166. 
96. Alan L, Mille ND. Antioxidant Flavonoids: Structure, Function and Clinical Usage 
Alternative Medicine Review. 1996;1(2):103-111. 
97. Shohaib T, Shafique M, Dhanya N, Madhu C, Divakar. Importance of Flavonoides in 
therapeutics Hygeia. J.D. Med. 20ll;3(1):1-18. 
98. Mukesh N, Ojha S K, Arya D S. Protective role of flavonoids in cardiovascular diseases. 
2005;4(3):83-97. 
99. A. D. Agrawal. Pharmacological Activities of Flavonoids: A Review. 2011; 4(2):13-28. 
100. Tapas AR, Sakarkar DM, Kakde RB. Flavonoids as Nutraceuticals: A Review Tropical 
Journal of Pharmaceutical Research. 2008;7(3):1089-1099. 
101. Leelavinothan P, Subramani S. Antihyperglycemic effect of diosmin on hepatic key 
enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic 
rats Biomedicine & Pharmacotherapy. 2010;64:477–481. 
102. Tang NP, Zhou B, Wang B, Yu RB, Ma J. Flavonoids intake and risk of lung cancer: a 
meta-analysis. Jpn JClin Oncol. 2009;39:352-359. 
103. Miyake Y, Yamamoto K, Tsujihara N, Osawa T: Protective effects of lemon flavonoids 
on oxidative stress in diabetic rats. Lipids 1998,33:689-695. 
104. Minato K, Miyake Y, Fukumoto S, Yamamoto K, Kato Y, Shimomura Y, Osawa T: 
Lemon flavonoid, eriocitrin, suppresses exerciseinduced oxidative damage in rat liver. 
Life Sci.  2003;72:1609-1616. 
105. Santhosh M, Selvam R. Supplementation of vitamin E and Selenium prevents 
hyperoxaluria in experimental urolithic rats. J Nutr Biochem 2003; 14:306-313. 
97 
 
106. Mackay J, Jemal A, Lee NC, Parkin DM. The Cancer Atlas. Atlanta, GA: American 
Cancer Society. 20011;61(2):63-134. 
107. Monograph on Diosmin. Alternative Medicine Review 2004;9(3):308-311. 
108. Cova D, De Angelis L, Giavarini F, et al. Pharmacokinetics and metabolism of oral 
diosmin in healthy volunteers. Int J ClinPharmacol Ther Toxicol. 1992;30:29-33. 
109. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of 
its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 
2003;63:71-100. 
110. Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic 
venous insufficiency. Angiology 2001;52:S49-S56. 
111. Tanaka T, Makita H, Ohnishi M. Chemoprevention of 4-nitroquinoline 1-oxideinduced 
oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in 
combination. Cancer Res. 1997;57:246-252. 
112. Casley-Smith JR, Casley-Smith JR. The effects of diosmin (a benzo-pyrone) upon some 
highprotein oedemas: lung contusion, and burn and lymphoedema of rat legs. Agents 
Actions. 1985;17:14-20. 
113. Lacombe C, Bucherer C, Lelievre JC. Hemorheological improvement after Daflon 500 
mg treatment in diabetes. Int Angiol. 1988;7:21-24. 
114. Erika Garcı´a-Cha´vez. Lipid oxidative damage and distribution of inorganic arsenic and 
its metabolites in the rat nervous system after arsenite exposure: Influence of alpha 
tocopherol supplementation. NeuroToxicology 27 (2006) 1024–1031. 
115. Omar M.E. Abdel-Salam. Neuroprotective and hepatoprotective effects of micronized 
purified flavonoid fraction (Daflon®) in lipopolysaccharide-treated rats. Drug 
Discoveries & Therapeutics. 2012; 6(6):306-314. 
116. Yusuf Tanrikulu. Th e protective eff ect of diosmin on hepatic ischemia reperfusion 
injury: an experimental study. Bosn J Basic Med Sci 2013; 13 (4): 218-224. 
117. John B. Protective effect of Diosmin against experimentally induced non alcoholic 
steatohepatitis. Asian. J. Biol. Sci. 2013. 
118. Ivan V. Batchvarov. One-year diosmin therapy (600 mg) in patients with Chronic venous 
insufficiency – results and analysis. J Biomed Clin Res Volume 3 Number 1, 2010. 
98 
 
119. Sergeeva E.О. study of protective action diosmin, hesperidin and "detralex" at 
Hepatotoxicity. 
120. V. Maksimovic. Medicamentous treatment of chronic venous insufficiency using 
semisynthetic diosmin – a prospective study. ACI Vol. LV. 
121. Takuji Tanaka. Modulation of N-methyl-N-amylnitrosamine-induced rat oesophageal 
tumourigenesis by dietary feeding of diosmin and hesperidin, both alone and in 
combination. Carcinogenesis vol.18 no.4 pp.761–769, 1997. 
122. Leelavinothan Pari. Antihyperglycemic effect of diosmin on hepatic key enzymes of 
carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. 
Biomedicine & Pharmacotherapy 64 (2010) 477–481. 
123. Jean-Pierre Savineau & Roger Marthan. Diosmin-induced increase in sensitivity to Ca2+ 
of the smooth muscle contractile apparatus in the rat isolated femoral vein. Br. J. 
Pharmacol. 1994. 
124. Nuria A´ lvarez. Synergistic Effect of Diosmin and Interferon-a on Metastatic Pulmonary 
Melanoma. Cancer Biotherapy And Radiopharmaceuticals Volume 24, Number 3. 2008. 
125. Subramani Srinivasan, Leelavinothan Pari. Ameliorative effect of diosmin, a citrus 
flavonoid against streptozotocinnicotinamide generated oxidative stress induced diabetic 
rats. Chemico-Biological Interactions 195 (2012) 43–51. 
126. Nianting Tong, Zhenzhen Zhang. Diosmin Alleviates Retinal Edema by Protecting the 
Blood-Retinal Barrier and Reducing Retinal Vascular Permeability during 
Ischemia/Reperfusion Injury. PLOS ONE. April 2013 | Volume 8 | Issue 4 | e61794. 
127. Hye Hyun Yoo. Effects of Diosmin, a Flavonoid Glycoside in Citrus Fruits, on P-
Glycoprotein-Mediated Drug Efflux in Human Intestinal Caco-2 Cells. J. Agric. Food 
Chem. 2007, 55, 7620-7625. 
128. Anne M. Melin. In Vivo Effect of Diosmin on Carrageenan and CC1,- Induced Lipid 
Peroxidation in Rat Liver Microsomes. J Biochem Toxicology Volume 11, Number 
1,1996. 
129. Ali Noorafshan, Saied Karbalay-Doust, Fatemeh Karimi. Diosmin Reduces Calcium 
Oxalate Deposition and Tissue Degeneration in Nephrolithiasis in Rats: A Stereological 
Study. Korean J Urol 2013;54:252-257. 
99 
 
130. C. Martínez. The effect of the flavonoid diosmin, grape seed extract and red wine on the 
pulmonary metastatic B16F10 melanoma. Histol Histopathol (2005) 20: 1121-1129. 
131. Alptekin Yasım. The effect of diosmin-hesperidin combination treatment on the lipid 
profile and oxidative-antioxidative system in high-cholesterol diet-fed rats. Türk Göğüs 
Kalp Damar Cer Derg 2011;19(1):55-61. 
132. Mokhtar I. Yousef and Fatma M. El-Demerdash. Sodium arsenite induced biochemical 
perturbations in rats: Ameliorating effect of curcumin. Food and Chemical Toxicology 46 
(2008) 3506–3511. 
133. Parmar RK, Kachchi NR, Tirgar PR, Desai TR. preclinical evalution of antiurolithiatic 
activity of swertiachiratastems Bhalodiya PN IRJP.  2012;3(8):198-202. 
134. Fawcett JK, Scott JE. A rapid and precise method for determination of urea. J ClinPathol. 
1960;13:156-9. 
135. Allan G. Gornall, Charles J. Bardawill, and Maxima M. David. determination of serum 
proteins by means of the biuret reaction.1948. 
136. Laboratory Procedure Manual for Total Cholesterol, HDL-Cholesterol, Triglycerides, and 
LDL-Cholesterol. Hitachi 704 Analyzer which is serviced by Roche Diagnostics 
(formerly Boehringer-Mannheim Diagnostics), Indianapolis. 
137. Sun AY and Chen AM. Oxidative stress and neurodegenerative disorder. Biomed Sci, 
1998, 5, 401-441. 
138. Chaudhary G, Sharma U, Jagannathan NR, Gupta YK. Evaluation of Withania somnifera 
in a middle cerebral artery occlusion model of stroke in rats. Clin Exp Pharmacol Physiol 
, 2003, 30, 399–404. 
139. Park EM, Choi JH, Park JS, Han MY, Park YM. Measurement of glutathione oxidation 
and 8 hydroxy 2c deoxyguanosine accumulation in the gerbil hippocampus following 
global ischemia. Brain Res Brain Res Protoc. 2000, 6, 25-32.  
140. Rajesh S. Yadav. Neuroprotective effect of curcumin in arsenic-induced neurotoxicity in 
rats. NeuroToxicology 31 (2010) 533–539. 
 
 
 
100 
 
 
